Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bacterial Infections and Mycoses
  Free Subscription

Articles published in
J Antimicrob Chemother
    December 2025
  1. CANAS MA, Cuervo G, Garcia-Gonzalez J, Krivak F, et al
    In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis.
    J Antimicrob Chemother. 2025 Dec 4:dkaf435. doi: 10.1093.
    >> Share

  2. PALACIOS R, Gomez-Ayerbe C, Martin-Cortes S, Gonzalez-Jimenez A, et al
    Post-exposure prophylaxis with doxycycline (DoxyPEP) to prevent STIs in a real-world setting: the PRIDOX study.
    J Antimicrob Chemother. 2025;80:3306-3310.
    >> Share

  3. REZZOUG I, Ouacel K, Droit T, Ronsin S, et al
    Therapeutic challenges in treating ESBL- and/or AmpC-producing non-carbapenemase-producing Enterobacterales: an in vitro evaluation of novel beta-lactam/beta-lactamase inhibitor combinations and cefiderocol.
    J Antimicrob Chemother. 2025;80:3297-3305.
    >> Share

  4. FU Y, Fouad A, Roenfanz HF, Nicolau DP, et al
    Efficacy of human-simulated aztreonam-avibactam against Stenotrophomonas maltophilia in the neutropenic murine thigh infection model.
    J Antimicrob Chemother. 2025;80:3431-3437.
    >> Share

  5. NEOH CF, Yong MK, Rowley L, Roberts AW, et al
    Antifungal prophylaxis in patients with FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia receiving sorafenib during initial induction and consolidation treatment in ALLG AMLM16 trial.
    J Antimicrob Chemother. 2025;80:3401-3406.
    >> Share

  6. ZHANG H, Liang B, Tan Z, Wang R, et al
    The synergistic activity of tigecycline-based combinations against multidrug-resistant Acinetobacter baumannii-caused bloodstream infections.
    J Antimicrob Chemother. 2025;80:3407-3418.
    >> Share

  7. VAN RHIJN N, White PL
    Antifungal treatment strategies and their impact on resistance development in clinical settings.
    J Antimicrob Chemother. 2025;80:3208-3226.
    >> Share

  8. ORENBUCH-HARROCH E, Snoyman G, Nashashibi MA, Temper V, et al
    Aztreonam-amoxicillin/clavulanate combination therapy against blaNDM-producing Enterobacterales infections.
    J Antimicrob Chemother. 2025;80:3375-3380.
    >> Share

  9. MULLER SE, Junker S, Rehner J, Forster M, et al
    Comparative in vitro activity of ceftazidime-avibactam plus aztreonam and the fixed combination aztreonam/avibactam against multidrug-resistant Pseudomonas aeruginosa.
    J Antimicrob Chemother. 2025;80:3352-3356.
    >> Share

  10. SMITH S, Reilly CW, Stewart J, Ragh T, et al
    Thrice-weekly post-haemodialysis ceftazidime can achieve adequate pre-dialysis concentrations and clinical cure in patients with melioidosis.
    J Antimicrob Chemother. 2025;80:3386-3390.
    >> Share

  11. PELLEGRINO C, Veronese N, De Santis L, Amendolara A, et al
    Frailty Index Laboratory (FI-Lab) as predictor of poor outcomes for intra-hospital multidrug-resistant Klebsiella pneumoniae bloodstream infections: a single-centre retrospective cohort study.
    J Antimicrob Chemother. 2025;80:3257-3264.
    >> Share

  12. BLANCO-MARTIN T, Guzman-Puche J, Hernandez-Garcia M, Munoz-Rosa M, et al
    Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes.
    J Antimicrob Chemother. 2025;80:3265-3272.
    >> Share

  13. MA J, van Doodewaerd BR, Biersack B, Verbon A, et al
    A drug-repurposing screen of FDA- and EMA-approved drugs identifies two NF-kappaB inhibitors active against eumycetoma.
    J Antimicrob Chemother. 2025;80:3320-3328.
    >> Share

  14. BALTAS I, Tsakri D, Vourli S, Solanki H, et al
    Comparative evaluation of disc diffusion and broth microdilution methods for aztreonam/avibactam susceptibility testing in Enterobacterales.
    J Antimicrob Chemother. 2025;80:3273-3277.
    >> Share

    November 2025
  15. TORUMKUNEY D, Mokaddas E, Weber S, Morrissey I, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Kuwait and the United Arab Emirates: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    J Antimicrob Chemother. 2025;80.
    >> Share

  16. TORUMKUNEY D, Van PH, Thinh LQ, Hawser S, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2020-21 in Vietnam: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    J Antimicrob Chemother. 2025;80.
    >> Share

  17. TORUMKUNEY D, Veeraraghavan B, Patil N, Dias M, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in India: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    J Antimicrob Chemother. 2025;80.
    >> Share

  18. TORUMKUNEY D, Keles N, Hasdemir U, Hazirolan G, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Turkiye: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    J Antimicrob Chemother. 2025;80.
    >> Share

  19. TORUMKUNEY D, Slim L, Hammami A, Hawser S, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Tunisia: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    J Antimicrob Chemother. 2025;80.
    >> Share

  20. TORUMKUNEY D, Bratus E, Yuvko O, Pertseva T, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    J Antimicrob Chemother. 2025;80.
    >> Share

  21. TORUMKUNEY D, Nizamuddin S, Morrissey I, Manenzhe R, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    J Antimicrob Chemother. 2025;80.
    >> Share

  22. TORUMKUNEY D, Canton R, Pitart C, Sanguinetti M, et al
    Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Italy and Spain: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
    J Antimicrob Chemother. 2025;80.
    >> Share

  23. LEE GY, Yang SJ
    Co-carriage of the oxazolidinone resistance genes cfr and optrA in a linezolid-resistant Staphylococcus rostri isolate from a pig-farm worker.
    J Antimicrob Chemother. 2025 Nov 20:dkaf428. doi: 10.1093.
    >> Share

  24. ALMEIDA-SANTOS AC, Tedim AP, Duarte B, Silva LM, et al
    Unnoticed spread of linear VanA-plasmids in vancomycin-variable Enterococcus faecium strains across different regions: a diagnostics challenge.
    J Antimicrob Chemother. 2025 Nov 20:dkaf409. doi: 10.1093.
    >> Share

  25. BENSACI MF, Bauer KA, Klinker K, Cota J, et al
    Post-pandemic trends in Streptococcus pneumoniae serotype epidemiology and antibiotic susceptibility in adults with invasive and non-invasive pneumococcal disease in the USA (2022-2023).
    J Antimicrob Chemother. 2025 Nov 20:dkaf414. doi: 10.1093.
    >> Share

  26. ASHRIN A, Hagenimana C, Jacquier H, Ourghanlian C, et al
    Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium.
    J Antimicrob Chemother. 2025 Nov 17:dkaf426. doi: 10.1093.
    >> Share

  27. LU R, Li X, Yang W, Chen J, et al
    In vitro activity of contezolid and other comparators against clinical Staphylococcus and Enterococcus: a multicenter study in China.
    J Antimicrob Chemother. 2025;80:3011-3020.
    >> Share

  28. TOYTING-HIRAISHI J, Sato T, Tohyama M, Fujino T, et al
    Potential human health risk of carbapenem-non-susceptible Pseudomonas aeruginosa from companion animals.
    J Antimicrob Chemother. 2025;80:3043-3056.
    >> Share

  29. GRAFIA I, Moll-Febrer A, Santillan SJ, Rodrigo C, et al
    Multidrug resistance and recurrence in urinary bacteraemia among cancer patients.
    J Antimicrob Chemother. 2025;80:3026-3033.
    >> Share

  30. SOW O, Oueslati S, Ndiaye I, Vanparis O, et al
    Molecular insights into carbapenemase-producing Enterobacterales from Senegal.
    J Antimicrob Chemother. 2025;80:2989-3000.
    >> Share

  31. JIANG X, Cao D, Qiu Y, Dong X, et al
    Novel mutations associated with clofazimine resistance in Mycobacterium intracellulare.
    J Antimicrob Chemother. 2025;80:2954-2957.
    >> Share

  32. NARONGPUN P, Chanchaithong P, Tanomsridachchai W, Nuanmuang N, et al
    Emergence of livestock-associated MRSA clonal complex 398 in Thailand's swine industry.
    J Antimicrob Chemother. 2025;80:2912-2917.
    >> Share

  33. BOYD SE, Wootton M, Howe RA, Livermore DM, et al
    Rifampicin as monotherapy for infections caused by Staphylococcus aureus: considerations for not applying 'breakpoints in brackets'.
    J Antimicrob Chemother. 2025 Nov 3:dkaf392. doi: 10.1093.
    >> Share

    October 2025
  34. REYNOLDS R, Mushtaq S, Hope R, Horner C, et al
    Antimicrobial resistance among Gram-negative agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019.
    J Antimicrob Chemother. 2025;80.
    >> Share

  35. REYNOLDS R, Mushtaq S, Hope R, Horner C, et al
    Antimicrobial resistance among Gram-positive agents of bacteraemia in the UK and Ireland: trends from 2001 to 2019.
    J Antimicrob Chemother. 2025;80.
    >> Share

  36. HORNER C, Reynolds R, Mushtaq S, Chaudhry A, et al
    Trends of serotypes and resistance among Streptococcus pneumoniae in the UK and Ireland (1999-2019).
    J Antimicrob Chemother. 2025;80.
    >> Share

  37. MACGOWAN AP, Reynolds R, Parcell BJ, Livermore DM, et al
    Two decades of resistance surveillance by the British Society for Antimicrobial Chemotherapy: design, development, delivery, deficiencies and future directions.
    J Antimicrob Chemother. 2025;80.
    >> Share

  38. PARCELL BJ, Horner C, Reynolds R, Allen M, et al
    Applications and benefits of the British Society for Antimicrobial Chemotherapy Resistance Surveillance Project-legacy and future.
    J Antimicrob Chemother. 2025;80.
    >> Share

  39. ALLEN M, Reynolds R, Mushtaq S, Nsonwu O, et al
    The British Society for Antimicrobial Chemotherapy Resistance Surveillance Project: methods and limitations.
    J Antimicrob Chemother. 2025;80.
    >> Share

  40. LALOUM I, Bidaud AL, Recalt E, Schwarz P, et al
    Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus.
    J Antimicrob Chemother. 2025 Oct 27:dkaf393. doi: 10.1093.
    >> Share

  41. GREGSON A, Mowlaboccus S, Sudeep SM, Rizzo S, et al
    Dual beta-lactam synergy in Enterococcus faecalis and its relationship with penicillin-ceftriaxone infective endocarditis treatment outcomes.
    J Antimicrob Chemother. 2025 Oct 17:dkaf377. doi: 10.1093.
    >> Share

  42. LAI CC, Liu CY, Huang KJ, Huang YT, et al
    Global susceptibility profiles and potential resistance mechanisms of ceftazidime-avibactam-resistant, non-carbapenemase-producing carbapenem-resistant Enterobacterales: 2020-23 data from the Antimicrobial Testing Leadership and Surveillance.
    J Antimicrob Chemother. 2025 Oct 7:dkaf375. doi: 10.1093.
    >> Share

  43. YANG J, Jiang T, Zhang M, Xue J, et al
    Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones.
    J Antimicrob Chemother. 2025;80:2862-2872.
    >> Share

  44. LARKIN C, Valappil SP, Palanisamy N
    Global prevalence of nitrofurantoin-resistant uropathogenic Escherichia coli (UPEC) in humans: a systematic review and meta-analysis.
    J Antimicrob Chemother. 2025;80:2609-2621.
    >> Share

  45. HALIM J, Keane AP, Bouzo J, Aderibigbe T, et al
    Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms.
    J Antimicrob Chemother. 2025;80:2814-2824.
    >> Share

  46. ZAGHI I, Cricca M, Roberts JA, Brandolini M, et al
    Development of blood culture time-to-positivity as a pharmacodynamic indicator for monitoring antibiotic therapy against MDR Gram-negative bacteria.
    J Antimicrob Chemother. 2025;80:2705-2713.
    >> Share

  47. SMITH DJ, Murphy HR, Benedict K, Dailey Garnes NJM, et al
    Trends in antifungal use among hospitalized patients in the USA, 2018-23.
    J Antimicrob Chemother. 2025;80:2659-2664.
    >> Share

  48. KOENIG C, Yi F, Nicolau DP, Asempa TE, et al
    In vivo activity of ceftibuten-ledaborbactam oral combination against serine-beta-lactamase-producing Enterobacterales: an assessment in the pyelonephritis and cystitis murine model.
    J Antimicrob Chemother. 2025;80:2714-2718.
    >> Share

  49. KLEMENTOVA T, Zakoucka H, Bizova B, Unemo M, et al
    Cefixime versus benzathine penicillin G for the treatment of early syphilis-a randomized, controlled open label trial.
    J Antimicrob Chemother. 2025;80:2654-2658.
    >> Share

  50. SKOVMAND S, Norgaard C, Salado-Rasmussen K, Jensen JS, et al
    In vitro activity of thiamphenicol against drug-susceptible and drug-resistant strains of Mycoplasma genitalium.
    J Antimicrob Chemother. 2025;80:2676-2681.
    >> Share

  51. ONG SWX, Pinto R, Rishu A, Tong SYC, et al
    Clinical course of patients with bloodstream infections enrolled in the BALANCE clinical trial.
    J Antimicrob Chemother. 2025;80:2752-2758.
    >> Share

  52. OUDIANE L, Benyahia M, Salipante F, Dubois A, et al
    Clinical impact of the BCID2 and rapid AST VITEK(R) REVEALTM on antibiotic optimisation in critically ill patients with Gram-negative bloodstream infections: a quasi-experimental pre/post interventional study.
    J Antimicrob Chemother. 2025;80:2665-2675.
    >> Share

  53. ROGER C, Allaouchiche B, Quintao De Moraes D, Ulrich Feudjio O, et al
    Intrapulmonary concentrations of ceftobiprole high doses administered by continuous infusion in critically ill patients with community-acquired pneumonia.
    J Antimicrob Chemother. 2025;80:2644-2653.
    >> Share

  54. PATEL S, Mohayya S, Yassin A, Dao J, et al
    Effectiveness of piperacillin/tazobactam loading dose for extended infusion dosing among patients with Gram-negative bacteraemia.
    J Antimicrob Chemother. 2025;80:2635-2643.
    >> Share

    September 2025
  55. PINDER C, Lebedinec R, Oliver JD, Birch M, et al
    In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species.
    J Antimicrob Chemother. 2025 Sep 30:dkaf354. doi: 10.1093.
    >> Share

  56. CINCOTTA SE, Ostrowsky BE, Howard-Anderson J, Beekmann SE, et al
    Treatment preferences by infectious diseases clinicians for carbapenem-resistant Enterobacterales infections.
    J Antimicrob Chemother. 2025 Sep 30:dkaf371. doi: 10.1093.
    >> Share

  57. IACHKINE J, Alexandre K, Marlat C, Briant A, et al
    Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched cohort study.
    J Antimicrob Chemother. 2025 Sep 30:dkaf370. doi: 10.1093.
    >> Share

  58. GIARRATANA LR, Pirolo M, Roch FF, Conrady B, et al
    Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America.
    J Antimicrob Chemother. 2025 Sep 27:dkaf340. doi: 10.1093.
    >> Share

  59. DARLOW CA, Farrington N, Martson AG, Johnson A, et al
    Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary aspergillosis.
    J Antimicrob Chemother. 2025 Sep 24:dkaf355. doi: 10.1093.
    >> Share

  60. WITKOWSKA A, Biedrzycka M, Izdebski R, Literacka E, et al
    Assessment of an LC coupled with tandem MS (LC-MS/MS) tool in the detection of antimicrobial resistance mechanisms in Enterobacterales.
    J Antimicrob Chemother. 2025 Sep 24:dkaf339. doi: 10.1093.
    >> Share

  61. XU W, Yan P, Li Y, Sun B, et al
    The toxin-antitoxin system SavRS contributes to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus by mediating cell wall thickening.
    J Antimicrob Chemother. 2025 Sep 23:dkaf325. doi: 10.1093.
    >> Share

  62. ELADAWY M, Heslop N, Negus D, Thomas JC, et al
    Phenotype-genotype discordance in antimicrobial resistance profiles of Gram-negative uropathogens recovered from catheter-associated urinary tract infections in Egypt.
    J Antimicrob Chemother. 2025 Sep 23:dkaf352. doi: 10.1093.
    >> Share

  63. YANG P, Liu C, Zheng J, Yi J, et al
    Rapid replacement of blaKPC variant in ST11 carbapenem-resistant and hypervirulent Klebsiella pneumoniae contributed to ceftazidime/avibactam resistance during severe in vivo infection.
    J Antimicrob Chemother. 2025 Sep 18:dkaf337. doi: 10.1093.
    >> Share

  64. CUI W, Lu R, Huang S, Ma R, et al
    Comparative evaluation of broth microdilution and gradient diffusion methods in Burkholderia cepacia complex susceptibility testing: implications of transitioning to ECV-based interpretation.
    J Antimicrob Chemother. 2025;80:2530-2540.
    >> Share

  65. RACCAGNI AR, Diotallevi S, Lolatto R, Bruzzesi E, et al
    Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy.
    J Antimicrob Chemother. 2025;80:2484-2486.
    >> Share

  66. ERGUN M, Bruggemann RJM, Alanio A, Bentvelsen RG, et al
    Classifying patients with invasive fungal disease: towards a unified case definition?
    J Antimicrob Chemother. 2025;80:2337-2343.
    >> Share

  67. LEE Y, Seong J, Lee JA, Ahn JY, et al
    Comparing the mortality of patients with sepsis using empirical piperacillin/tazobactam and cefepime: analysis of the MIMIC-IV database.
    J Antimicrob Chemother. 2025;80:2487-2495.
    >> Share

  68. NAIR S, Barker CR, Patel V, Poh CY, et al
    Highly drug-resistant Vibrio cholerae harbouring blaPER-7 isolated from travellers returning to England.
    J Antimicrob Chemother. 2025;80:2428-2432.
    >> Share

  69. MAZZITELLI M, Coppi M, Scaglione V, Paci L, et al
    Clinical and microbiological analysis of bloodstream infections by four cefiderocol-resistant and not previously exposed NDM-producing Klebsiella pneumoniae.
    J Antimicrob Chemother. 2025;80:2442-2446.
    >> Share

  70. JACQUEMIN A, Palma F, Duque M, Jousset AB, et al
    A novel multilocus sequence typing scheme for Morganella spp.: population structure and introduction of quantitative metric for standardization of MLST scheme.
    J Antimicrob Chemother. 2025;80:2391-2398.
    >> Share

  71. TAN Z, Liang W, Zhang N, Liang B, et al
    Efficacy and safety of earlier switching to an oral antibiotic therapy for the treatment of Gram-positive bloodstream infections: a systematic review and meta-analysis.
    J Antimicrob Chemother. 2025;80:2344-2360.
    >> Share

  72. IMOLI D, Maingi JM, Mbae C, Kavai SM, et al
    Genomic characterization of multidrug-resistant extended-spectrum beta-lactamase-producing Vibrio cholerae O1 strains from 2022 cholera outbreak in Kenya.
    J Antimicrob Chemother. 2025;80:2399-2407.
    >> Share

  73. OLDBERG K, Rasmussen M
    Comment on: Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus.
    J Antimicrob Chemother. 2025 Sep 2:dkaf320. doi: 10.1093.
    >> Share

    August 2025
  74. GELE T, Atwine D, Baudin E, Muyindike W, et al
    Pharmacokinetics of rifampicin and isoniazid in patients with HIV-tuberculosis coinfection receiving efavirenz-based antiretroviral treatment: an ANRS12292-RIFAVIRENZ sub-study.
    J Antimicrob Chemother. 2025 Aug 29:dkaf319. doi: 10.1093.
    >> Share

  75. HAO J, Lu F, Chen P, Ji C, et al
    Characterization of blaOXA-542-mediated carbapenem resistance in Acinetobacter baumannii.
    J Antimicrob Chemother. 2025 Aug 29:dkaf311. doi: 10.1093.
    >> Share

  76. LI J, Hou W, Chang J, Tian X, et al
    The pivotal role of acnA in linking carbon metabolism to virulence and antimicrobial resistance in methicillin-resistant Staphylococcus aureus.
    J Antimicrob Chemother. 2025 Aug 28:dkaf317. doi: 10.1093.
    >> Share

  77. MCCRACKEN M, Walkty A, Adam HJ, Baxter M, et al
    Characterization of carbapenem-resistant Pseudomonas aeruginosa in Canadian hospitals: 6 years of the CANWARD study (2018-23).
    J Antimicrob Chemother. 2025;80.
    >> Share

  78. MATASEJE LF, Lerminiaux N, Lagace-Wiens P, Walkty A, et al
    Characterization of ertapenem-resistant Enterobacterales in Canadian hospitals: 17 years of the CANWARD study (2007-23).
    J Antimicrob Chemother. 2025;80.
    >> Share

  79. ADAM HJ, Golden AR, Martin I, Baxter MR, et al
    Comparison of antimicrobial resistance and serotype patterns in Streptococcus pneumoniae from blood cultures and respiratory specimens in Canadian hospitals from the CANWARD study (2007-23).
    J Antimicrob Chemother. 2025;80.
    >> Share

  80. BRAHAMI A, Karlowsky JA, McCracken M, Golding GR, et al
    Characterization of methicillin-resistant Staphylococcus aureus in Canadian hospitals: 17 years of the CANWARD study (2007-23).
    J Antimicrob Chemother. 2025;80.
    >> Share

  81. WALKTY A, Adam HJ, Baxter M, Karlowsky JA, et al
    Distribution and antimicrobial susceptibility profile of pathogens recovered from the bloodstream of Canadian patients: results from the CANWARD study (2007-23).
    J Antimicrob Chemother. 2025;80.
    >> Share

  82. ZHANEL GG, Baxter MR, Lagace-Wiens P, Walkty A, et al
    Gram-negative pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007-23).
    J Antimicrob Chemother. 2025;80.
    >> Share

  83. ZHANEL GG, Baxter MR, Golden AR, Lagace-Wiens P, et al
    Gram-positive pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007-23).
    J Antimicrob Chemother. 2025;80.
    >> Share

  84. LAGACE-WIENS P, Mataseje L, McCracken M, Walkty A, et al
    Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007-23.
    J Antimicrob Chemother. 2025;80.
    >> Share

  85. SUN Y, McGiffin D, Ye L, Kostoulias X, et al
    Low bacterial metabolism as a central mechanism of antimicrobial resistance and potential therapeutic target of staphylococcal biofilms in ventricular assist device driveline infections.
    J Antimicrob Chemother. 2025 Aug 26:dkaf316. doi: 10.1093.
    >> Share

  86. CERCENADO E, Marin M, Iglesias M, Jimenez L, et al
    Molecular characterization of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae susceptible to delafloxacin.
    J Antimicrob Chemother. 2025 Aug 21:dkaf308. doi: 10.1093.
    >> Share

  87. SAMUELSSON T, Lonnermark E, Sundell J, Yilmaz A, et al
    Rifampicin concentrations throughout the entire treatment duration of active tuberculosis; impact of sex and body mass index.
    J Antimicrob Chemother. 2025 Aug 21:dkaf300. doi: 10.1093.
    >> Share

  88. MANCINI S, Seth-Smith HMB, Kolesnik-Goldmann N, Mermod M, et al
    Performance of disc diffusion and gradient strip test on different Mueller-Hinton agar media plates and ComASP(R) and Bruker UMIC(R) Cefiderocol Microdilution Panels for cefiderocol susceptibility testing in carbapenem-resistant Pseudomonas aeruginosa
    J Antimicrob Chemother. 2025 Aug 18:dkaf301. doi: 10.1093.
    >> Share

  89. VAN DER FELTZ I, Wen H, Aarnoutse RE, Magis-Escurra C, et al
    Studying intrapulmonary pharmacokinetics for tuberculosis treatment: a systematic review of methodology.
    J Antimicrob Chemother. 2025 Aug 14:dkaf274. doi: 10.1093.
    >> Share

  90. BALAKUNTLA J, Simjee S, Mane SP, Tice G, et al
    Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates.
    J Antimicrob Chemother. 2025 Aug 7:dkaf296. doi: 10.1093.
    >> Share

  91. ZENG Q, Huang H, Lu J, Wu L, et al
    Comparative outcomes of polymyxins in neurocritical care patients with carbapenem-resistant Gram-negative bacterial pneumonia: a retrospective cohort study.
    J Antimicrob Chemother. 2025 Aug 7:dkaf295. doi: 10.1093.
    >> Share

  92. BIERGE P, Gomez-Sanchez I, Garcia de la Maria C, Sanchez-Osuna M, et al
    Is ampicillin plus cephalosporins a therapeutic option for Ampicillin-Susceptible Enterococcus faecium?
    J Antimicrob Chemother. 2025 Aug 6:dkaf226. doi: 10.1093.
    >> Share

  93. ANASTASSOPOULOU C, Panagiotopoulos AP, Ferous S, Tsakris A, et al
    Phages connect the biological dots of antimicrobial resistance: from genesis and spread to alternative treatment modules.
    J Antimicrob Chemother. 2025 Aug 6:dkaf293. doi: 10.1093.
    >> Share

  94. BASOULIS D, Gkoufa A, Mastrogianni E, Pantazatou A, et al
    Comparison of ceftolozane/tazobactam and meropenem in treating bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacterales: a single-centre, retrospective, real-world study.
    J Antimicrob Chemother. 2025;80:2314-2322.
    >> Share

  95. POIGNON C, Dortet L, Birer A, Rezzoug I, et al
    Characterization of Carbapenemase-producing Enterobacterales isolated from patients returning from Sub-Saharan Africa, France, 2015-2022.
    J Antimicrob Chemother. 2025;80:2285-2294.
    >> Share

  96. KOELE SE, Stoycheva K, Mtweve C, Manyama C, et al
    Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB.
    J Antimicrob Chemother. 2025;80:2305-2313.
    >> Share

  97. JIN Y, Zhou W, Chen W, Xiao Y, et al
    Penicillin-susceptible ST398 with strong biofilm-forming ability poses a significant threat to osteoarticular infections.
    J Antimicrob Chemother. 2025;80:2295-2304.
    >> Share

  98. MOGUET C, Oueslati S, Vanparis O, Cisse L, et al
    Development and evaluation of a novel rapid immunochromatographic assay for the detection of DHA-producing Enterobacterales.
    J Antimicrob Chemother. 2025;80:2241-2246.
    >> Share

  99. BRENCIANI A, Massacci FR, Albini E, Cucco L, et al
    Novel integrative and conjugative elements carrying cfr(B) and cfr(C) linezolid resistance genes in Clostridioides difficile isolates from calves, Italy.
    J Antimicrob Chemother. 2025;80:2280-2284.
    >> Share

  100. SADER HS, Kimbrough JH, Winkler ML, Castanheira M, et al
    Aztreonam/avibactam activity against Enterobacterales from European medical centres: summary of 5 years of surveillance prior to approval for clinical use (2019-2023).
    J Antimicrob Chemother. 2025;80:2070-2079.
    >> Share

  101. WANG A, Liu P, Wu Y, Ma R, et al
    Optimization and improvement of the disc diffusion method for mucoid Pseudomonas aeruginosa.
    J Antimicrob Chemother. 2025;80:2117-2125.
    >> Share

  102. TANIGUCHI J, Aso S, Matsui H, Fushimi K, et al
    Outcomes of ceftriaxone 2 g versus 1 g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study.
    J Antimicrob Chemother. 2025;80:2194-2202.
    >> Share

  103. SHAFIQ N, Kumar A, Vohra V, Khuller GK, et al
    Four-month clofazimine regimen for susceptible pulmonary TB: a randomized clinical trial.
    J Antimicrob Chemother. 2025;80:2100-2108.
    >> Share

    July 2025
  104. FERRANDO ML, Saluzzo F, Frederiksen RF, Slettemeas JS, et al
    Determination of epidemiological cut-off values for Narasin, Salinomycin, Lasalocid and Monensin in Enterococcus faecium.
    J Antimicrob Chemother. 2025 Jul 31:dkaf113. doi: 10.1093.
    >> Share

  105. MELETIADIS J, Guinea J, Arikan-Akdagli S, Meijer EFJ, et al
    A multicentre study for determination of epidemiological cut-off values for Candida auris with EUCAST broth microdilution reference methodology.
    J Antimicrob Chemother. 2025 Jul 29:dkaf241. doi: 10.1093.
    >> Share

  106. LUQUE PAZ D, Turban A, Guerin F, Penven M, et al
    Paradoxical interaction between dalbavancin and beta-lactams against endocarditis-associated Enterococcus faecalis clinical isolates.
    J Antimicrob Chemother. 2025 Jul 28:dkaf262. doi: 10.1093.
    >> Share

  107. CHEN X, Ouyang F, Wang N, Liu D, et al
    Synergistic effects of DHA27 combined with gentamicin against methicillin-resistant Staphylococcus aureus in vitro and in vivo.
    J Antimicrob Chemother. 2025 Jul 25:dkaf239. doi: 10.1093.
    >> Share

  108. NODA M, Furuta A, Yashima S, Yaguchi D, et al
    Fluctuations in copy number of the class A carbapenemase gene blaFRI appear to confer high-level carbapenem resistance.
    J Antimicrob Chemother. 2025 Jul 25:dkaf258. doi: 10.1093.
    >> Share

  109. DEL MONTE M, Kaleci S, Chester J, Zerbato V, et al
    Impact of vancomycin resistance on attributable mortality among Enterococcus faecium bloodstream infections: propensity score analysis of a large, multicentre retrospective study.
    J Antimicrob Chemother. 2025 Jul 22:dkaf242. doi: 10.1093.
    >> Share

  110. MORETO-CASTELLSAGUE C, Gonzalez-Diaz A, Escrihuela-Vidal F, Calvo-Silveria S, et al
    In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization.
    J Antimicrob Chemother. 2025 Jul 22:dkaf260. doi: 10.1093.
    >> Share

  111. OU TH, Yang JL, Lin CY, Huang SH, et al
    Impact of empiric anti-VRE therapy on survival in vancomycin-resistant enterococcal bloodstream infection.
    J Antimicrob Chemother. 2025 Jul 17:dkaf225. doi: 10.1093.
    >> Share

  112. SPRUIJTENBURG B, de Groot T, Meijer EFJ
    SCY-247, a novel second-generation triterpenoid antifungal, demonstrates high in vitro activity against genetically diverse Candida auris isolates, including FKS1 mutants.
    J Antimicrob Chemother. 2025 Jul 17:dkaf240. doi: 10.1093.
    >> Share

  113. SINGH S, Adhikari S, Varshney N, Rani C, et al
    Overcoming antimicrobial resistance in Helicobacter pylori: the roles of collateral sensitivity and biofilm dynamics.
    J Antimicrob Chemother. 2025 Jul 15:dkaf233. doi: 10.1093.
    >> Share

  114. TURICCHI G, Bongiovanni M
    Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option?
    J Antimicrob Chemother. 2025 Jul 8:dkaf215. doi: 10.1093.
    >> Share

  115. VAN DEN BIGGELAAR RHGA, Erdkamp D, de Visser AW, van den Eeden SJF, et al
    Indolocarbazoles as host-directed therapeutics against intracellular infections by methicillin-resistant Staphylococcus aureus.
    J Antimicrob Chemother. 2025 Jul 1:dkaf198. doi: 10.1093.
    >> Share

  116. THORLEY EV, Hatch J, Li M, Mashida SN, et al
    Liposomal amphotericin B prophylaxis in paediatrics: a systematic review.
    J Antimicrob Chemother. 2025;80:1792-1802.
    >> Share

  117. RANGANATH N, Tabaja H, Nair VO, Dumais M, et al
    Lines on the line: evaluating the impact of antibiotic lock therapy versus catheter removal in the management of central vascular catheter infections.
    J Antimicrob Chemother. 2025;80:2016-2024.
    >> Share

  118. CHUA TP, Danielewski J, Bradshaw CS, Machalek DA, et al
    A novel azithromycin resistance mutation in Mycoplasma genitalium induced in vitro.
    J Antimicrob Chemother. 2025;80:2044-2050.
    >> Share

  119. GONCALVES AB, Alves V, Neves I, Read A, et al
    Real-time FT-IR typing of Klebsiella pneumoniae: a flexible and rapid approach for outbreak detection and infection control.
    J Antimicrob Chemother. 2025;80:2025-2031.
    >> Share

  120. PARANOS P, Siopi M, Papanikolaou E, Vourli S, et al
    Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations.
    J Antimicrob Chemother. 2025;80:1997-2006.
    >> Share

  121. KRZYZEK P, Opalinska A, Migdal P, Tusiewicz K, et al
    Antibiotic stress affects the secretion and physicochemical features of extracellular vesicles produced by Helicobacter pylori.
    J Antimicrob Chemother. 2025;80:2032-2043.
    >> Share

  122. ROSCA AS, Chaponda EB, Beckers T, De Koning HP, et al
    Repurposing antimalarials: pyrimethamine exhibits superior in vitro activity to metronidazole against Gardnerella while sparing Lactobacillus.
    J Antimicrob Chemother. 2025;80:1972-1979.
    >> Share

  123. KOONG J, Hall RM, Hamidian M
    Genomic characteristics of the multiresistant Acinetobacter baumannii global clone 1 reference strain A297/RUH875.
    J Antimicrob Chemother. 2025;80:1988-1992.
    >> Share

  124. ATTWOOD MLG, Noel A, Griffin P, Racine E, et al
    In vitro activity of NOSO-502, a novel-action antimicrobial, against clinical strains of Enterobacterales including MDR strains.
    J Antimicrob Chemother. 2025;80:1942-1946.
    >> Share

  125. DAVIDSON HC, Yau T, Dunstan I, Houston A, et al
    Early use of the novel antifungal rezafungin: a case series and literature review.
    J Antimicrob Chemother. 2025;80:1885-1892.
    >> Share

    June 2025
  126. RINALDI M, Rancan I, Malerba F, Gatti M, et al
    Enterococcus faecium bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes.
    J Antimicrob Chemother. 2025 Jun 19:dkaf197. doi: 10.1093.
    >> Share

  127. ZHENG YD, Xu J, Wu J, Zhong T, et al
    Oleanolic acid derivative bardoxolone combats multidrug-resistant Staphylococcus aureus by destroying cell membrane and pyruvate metabolism pathway.
    J Antimicrob Chemother. 2025 Jun 10:dkaf190. doi: 10.1093.
    >> Share

  128. KIHLBERG P, Bech Johannesen T, Stegger M, Cajander S, et al
    Reliability of disc diffusion testing and molecular epidemiology of penicillin-susceptible Staphylococcus aureus bacteraemia.
    J Antimicrob Chemother. 2025 Jun 10:dkaf187. doi: 10.1093.
    >> Share

  129. EL NAGAR A, Dewe TCM, Broadfoot F, Teale C, et al
    Decreasing antimicrobial resistance in representative UK livestock species was associated with reduced total sales of antimicrobials in the last decade.
    J Antimicrob Chemother. 2025 Jun 5:dkaf145. doi: 10.1093.
    >> Share

  130. EDSLEV SM, Laurent F, Mansson E, Johannesen TB, et al
    Antibiotic resistance and population structure of Staphylococcus epidermidis from prosthetic joint infections in Sweden and France.
    J Antimicrob Chemother. 2025 Jun 3:dkaf166. doi: 10.1093.
    >> Share

  131. MA J, Eadie K, Konings M, Fahal A, et al
    Ibrexafungerp prolongs survival and reduces the eumycetoma grain size in Galleria mellonella infection models of two different causative agents of eumycetoma.
    J Antimicrob Chemother. 2025;80:1733-1741.
    >> Share

  132. HANDAL N, Kaspersen H, Mo SS, Cabanel N, et al
    A comparative study of the molecular characteristics of human uropathogenic Escherichia coli collected from two hospitals in Norway and France in 2019.
    J Antimicrob Chemother. 2025;80:1707-1715.
    >> Share

  133. CHEN WP, Chen CL, Siu LK, Chang FY, et al
    Antibiotic treatment of Stenotrophomonas maltophilia bacteraemia: does trimethoprim/sulfamethoxazole dose affect clinical outcomes?
    J Antimicrob Chemother. 2025;80:1716-1725.
    >> Share

  134. RODRIGUEZ-VILLODRES A, Soto-Gallego C, Ortiz De La Rosa JM, Rodriguez-Rodriguez M, et al
    Impact of the inoculum effect on cefepime activity against AmpC-hyperproducing Enterobacter spp.: insights into resistance mechanisms.
    J Antimicrob Chemother. 2025;80:1687-1693.
    >> Share

  135. CAMPANA-BURGUET A, Latorre-Fernandez J, Eguizabal P, Belles-Belles A, et al
    Changing epidemiology of MRSA-CC398 in Spanish hospitals located in areas with different pig farming densities: a 2023 multicentre study.
    J Antimicrob Chemother. 2025;80:1577-1586.
    >> Share

  136. KOCER K, Gopel L, Gisch S, Tueffers L, et al
    Detection of a novel SME-6 Carbapenemase in Serratia ureilytica in Germany.
    J Antimicrob Chemother. 2025;80:1682-1686.
    >> Share

  137. SASTRE-ESCOLA E, Ntziora F, Chiurlo M, Martin-Davila P, et al
    Ceftazidime/avibactam for the treatment of bloodstream infection due to carbapenemase-producing Enterobacterales in onco-haematologic neutropenic patients (the TARZAN study).
    J Antimicrob Chemother. 2025;80:1673-1681.
    >> Share

  138. ZHANG BL, Li H, Wang WX, Chen XZ, et al
    Depolymerase as a potent adjunct to polymyxin for targeting KL160 pandrug-resistant Acinetobacter baumannii in a murine bacteremia model.
    J Antimicrob Chemother. 2025;80:1613-1625.
    >> Share

  139. HAMZE H, Payne M, Stefanovic A, Lowe CF, et al
    Helicobacter pylori culture positivity and antimicrobial susceptibility profiles (Vancouver, Canada).
    J Antimicrob Chemother. 2025;80:1640-1646.
    >> Share

  140. ROBSON C, Liu X, Al-Mukhtar O, Wallis SC, et al
    Population pharmacokinetics and optimized prophylaxis dosing of cefazolin during transcatheter aortic valve implantation.
    J Antimicrob Chemother. 2025;80:1604-1612.
    >> Share

  141. BITAR M, Le Moigne V, Herrmann JL, Arthur M, et al
    In vitro, intracellular and in vivo synergy between amoxicillin, imipenem and relebactam against Mycobacterium abscessus.
    J Antimicrob Chemother. 2025;80:1560-1567.
    >> Share

  142. SARIA P, Doulidis PG, Desvars-Larrive A, Toth AG, et al
    Pandemic human-associated extended-spectrum beta-lactamase-producing Escherichia coli lineages of ST38, ST131 and ST141 identified in Viennese dogs.
    J Antimicrob Chemother. 2025;80:1573-1576.
    >> Share

  143. HOLLAND TL, Shorr AF, Overcash JS, Engelhardt M, et al
    Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trials.
    J Antimicrob Chemother. 2025;80:1526-1534.
    >> Share

  144. FRATONI AJ, Padgett AM, Duffy EM, Nicolau DP, et al
    Quantitative performance of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin against a challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa in a standardized neutropenic murine pneumonia mode
    J Antimicrob Chemother. 2025;80:1552-1559.
    >> Share

  145. GATTI M, Rinaldi M, Bonazzetti C, Siniscalchi A, et al
    A pre-post quasi-experimental study of the impact of TDM-guided aggressive pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftolozane/tazobactam monotherapy in treating severe Pseudomonas aeruginosa infections: a strategy use
    J Antimicrob Chemother. 2025;80:1543-1551.
    >> Share

    May 2025
  146. CHO H, Park KT
    A novel methicillin-resistant Staphylococcus aureus lineage (ST4174) with an uncharacterized SCCmec variant identified in Korean pigs.
    J Antimicrob Chemother. 2025 May 31:dkaf178. doi: 10.1093.
    >> Share

  147. SHAH S, Clarke LG, Balasubramani GK, Peng L, et al
    Impact of hypoalbuminemia on patients receiving ertapenem combination therapy for methicillin-susceptible Staphylococcus aureus bacteraemia.
    J Antimicrob Chemother. 2025 May 31:dkaf134. doi: 10.1093.
    >> Share

  148. HAYASHI Y, Takahashi M, Sasaki M, Suzuki K, et al
    Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium.
    J Antimicrob Chemother. 2025 May 29:dkaf175. doi: 10.1093.
    >> Share

  149. CANAS MA, Garcia-de-la-Maria C, Garcia-Gonzalez J, Jimenez MP, et al
    Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains.
    J Antimicrob Chemother. 2025 May 27:dkaf149. doi: 10.1093.
    >> Share

  150. KRISHNAPRASAD VH, Nayak V, Kumar S
    World Health Organisation's Bacterial Pathogen Priority List (BPPL) 2017 and BPPL 2024 to combat global antimicrobial resistance crisis: 'challenges and opportunities'.
    J Antimicrob Chemother. 2025 May 27:dkaf167. doi: 10.1093.
    >> Share

  151. MORIN A, Le Guen J, Benaboud S, Richebe P, et al
    Is cefazolin an option for treatment of staphylococcal endogenous endophthalmitis?
    J Antimicrob Chemother. 2025 May 26:dkaf165. doi: 10.1093.
    >> Share

  152. MOSIICHUK N, Enggren G, Da Silva ZL, Moren AK, et al
    Antibacterial activity of propylene glycol against Staphylococcus aureus and Staphylococcus epidermidis in neutral and mild acidic conditions.
    J Antimicrob Chemother. 2025 May 26:dkaf153. doi: 10.1093.
    >> Share

  153. HTAIK K, Vodstrcil LA, Plummer EL, Matthews LG, et al
    Efficacy and tolerability of the combination of minocycline and metronidazole for macrolide-resistant Mycoplasma genitalium.
    J Antimicrob Chemother. 2025 May 22:dkaf142. doi: 10.1093.
    >> Share

  154. VILLAMARIN M, Fernandez-Hidalgo N, Escola-Verge L
    Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre-a counterpoint.
    J Antimicrob Chemother. 2025 May 21:dkaf164. doi: 10.1093.
    >> Share

  155. BUTSCHEID Y, Frey PM, Pfister M, Pagani L, et al
    Decline of antimicrobial resistance in Pseudomonas aeruginosa bacteraemia following the COVID-19 pandemic: a longitudinal observational study.
    J Antimicrob Chemother. 2025 May 14:dkaf136. doi: 10.1093.
    >> Share

  156. VERA-YUNCA D, Matias C, Vingsbo Lundberg C, Friberg LE, et al
    Model-based translation of the PKPD-relationship for linezolid and vancomycin on methicillin-resistant Staphylococcus aureus: from in vitro time-kill experiments to a mouse pneumonia model.
    J Antimicrob Chemother. 2025 May 9:dkaf140. doi: 10.1093.
    >> Share

  157. DANNEELS P, Lemaignen A, Lorleac'h A, Talarmin JP, et al
    Comment on: Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre.
    J Antimicrob Chemother. 2025 May 8:dkaf138. doi: 10.1093.
    >> Share

  158. SINGH R, Mukherjee S, Harrision LB, McDermott PF, et al
    Cross-resistance to 14-, 15- and 16-membered ring macrolides in Salmonella and Campylobacter.
    J Antimicrob Chemother. 2025;80:1445-1452.
    >> Share

  159. KOELE SE, Heinrich N, De Jager VR, Dreisbach J, et al
    Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043.
    J Antimicrob Chemother. 2025;80:1315-1323.
    >> Share

  160. ATHANASSA Z, Papakyriakopoulou P, Marquez Megias S, Saitani EM, et al
    Population pharmacokinetic model of oral minocycline in critically ill adult patients with ventilator-associated pneumonia.
    J Antimicrob Chemother. 2025;80:1420-1426.
    >> Share

  161. PAIRMAN L, Beh YT, Maher H, Gardiner SJ, et al
    A retrospective observational cohort study of oral azithromycin treatment for Legionnaires' disease.
    J Antimicrob Chemother. 2025;80:1354-1361.
    >> Share

  162. PINA-SANCHEZ M, Rua M, Lopez-Causape C, Bilbao I, et al
    Ceftazidime-avibactam plus aztreonam cocktail for the treatment of VIM-producing Pseudomonas aeruginosa infections: good enough to have another?
    J Antimicrob Chemother. 2025;80:1371-1376.
    >> Share

  163. SKALLY M, Cafferkey J, Russell M, Mcbrierty L, et al
    Screening for carbapenemase-producing Enterobacterales (CPE)-considering the practical implications of molecular results, the value of culture and deciding criteria for resistance.
    J Antimicrob Chemother. 2025;80:1402-1406.
    >> Share

  164. AGGOUN D, Verdonk C, Bleibtreu A, Fekkar A, et al
    Prophylaxis against Pneumocystis jirovecii pneumonia and toxoplasmosis with low-dose Trimethoprim-sulfamethoxazole (cotrimoxazole 20/100 mg) in heart transplant patients. The PAPTO-LOCO observational comparative study.
    J Antimicrob Chemother. 2025;80:1394-1401.
    >> Share

  165. THENE L, Floch P, Chagneau CV, Dubois D, et al
    In vitro activity of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against clinical isolates of non-aeruginosa Pseudomonas.
    J Antimicrob Chemother. 2025;80:1296-1301.
    >> Share

  166. BAVARO DF, Accurso G, Corcione S, Vena A, et al
    Antipseudomonal cephalosporins versus piperacillin/tazobactam or carbapenems for the definitive antibiotic treatment of Pseudomonas aeruginosa bacteraemia: new kids on the ICU block?
    J Antimicrob Chemother. 2025;80:1342-1353.
    >> Share

  167. SINGH N, Dangi B, Johnson JJ, Louie A, et al
    Pharmacodynamic assessment of apramycin against Mycobacterium abscessus in a hollow fibre infection model.
    J Antimicrob Chemother. 2025;80:1309-1314.
    >> Share

  168. MATULUKO A, Mantzourani E, Ahmed H, Cannings-John R, et al
    Comparison of antibiotic provision associated with acute sore throat symptom management in community pharmacies in Wales and England: a natural policy experiment.
    J Antimicrob Chemother. 2025;80:1256-1260.
    >> Share

  169. VAN DEN BERG S, Sassen SDT, Couet W, Marchand S, et al
    The synergistic effect of the combination of polymyxin B and rifampicin in a murine neutropenic thigh infection model with E. coli and K. pneumoniae.
    J Antimicrob Chemother. 2025;80:1248-1255.
    >> Share

    April 2025
  170. LOCKE JB, Andes D, Flanagan S, Redell M, et al
    Activity of rezafungin against Candida auris.
    J Antimicrob Chemother. 2025 Apr 30:dkaf124. doi: 10.1093.
    >> Share

  171. METARFI Y, Chellal W, Ben Khadda Z, Hoummani H, et al
    Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review.
    J Antimicrob Chemother. 2025 Apr 21:dkaf126. doi: 10.1093.
    >> Share

  172. WASSELIN V, Budin-Verneuil A, Rince I, Desriac F, et al
    Tetracyclines at subinhibitory concentrations are lethal for NADH peroxidase-deficient mutants of Enterococcus faecium.
    J Antimicrob Chemother. 2025 Apr 10:dkaf105. doi: 10.1093.
    >> Share

  173. TALA-IGHIL T, Royer G, Lepeule R, Fihman V, et al
    Clinical features and medical-surgical management overweight the inoculum effect and genotypic characteristics of MSSA in infective endocarditis.
    J Antimicrob Chemother. 2025 Apr 10:dkaf115. doi: 10.1093.
    >> Share

  174. FIFER H, Johnson A
    The continuing evolution of antibiotic resistance in Neisseria gonorrhoeae: past, present and future threats to effective treatment.
    J Antimicrob Chemother. 2025 Apr 10:dkaf109. doi: 10.1093.
    >> Share

  175. KANG SW, Jang HM, Chang E, Bae S, et al
    Impact of fluoroquinolone exposure on the diagnosis and prognosis of tuberculosis in immunocompromised patients: a propensity-score-matched, competing risk analysis.
    J Antimicrob Chemother. 2025 Apr 7:dkaf111. doi: 10.1093.
    >> Share

  176. YAN T, Wang J, Zhu R, Ma D, et al
    Vonoprazan improves the efficacy of bismuth quadruple therapy containing doxycycline and metronidazole as first-line Helicobacter pylori treatment in penicillin-allergic patients: a randomized controlled trial.
    J Antimicrob Chemother. 2025;80:927-934.
    >> Share

  177. WEERDENBURG H, Walker H, Haeusler GM, Cole T, et al
    Relationship between posaconazole concentrations and clinical outcomes in paediatric cancer and haematopoietic stem cell transplant recipients.
    J Antimicrob Chemother. 2025;80:897-907.
    >> Share

  178. TELLAPRAGADA C, Dunleavy C, Jonsson P, Giske CG, et al
    Decreased susceptibility to cefepime/zidebactam among carbapenemase-producing Escherichia coli from Stockholm, Sweden with alterations in PBP2.
    J Antimicrob Chemother. 2025;80:1137-1140.
    >> Share

  179. SHIFERAW MW, Donnelley MA, Thompson GR 3rd
    Prevalence of antifungal allergies in the general population.
    J Antimicrob Chemother. 2025;80:1080-1083.
    >> Share

  180. KHANINA A, Singh N, James R, Kong DCM, et al
    Assessing the appropriateness of antifungal prescribing: key results from the implementation of a novel audit tool in Australian hospitals.
    J Antimicrob Chemother. 2025;80:1127-1136.
    >> Share

  181. HAENNI M, Murri S, Drapeau A, Rafidinarivo I, et al
    Emergence of MRSA ST612 in horses and of MSSA CC398 in cats in France.
    J Antimicrob Chemother. 2025;80:1001-1010.
    >> Share

  182. QIU H, Dai W
    Type IV PilD mutant stimulates the formation of persister cells in Pseudomonas aeruginosa.
    J Antimicrob Chemother. 2025;80:1031-1036.
    >> Share

  183. GRAVES ET, Wardlow L, Ogake S, Bazan JA, et al
    Comparison of trimethoprim-sulfamethoxazole versus minocycline monotherapy for treatment of Stenotrophomonas maltophilia pneumonia.
    J Antimicrob Chemother. 2025;80:988-995.
    >> Share

  184. JAKUBU V, Cechova M, Musilek M, Malisova L, et al
    Amino acid substitutions in PBP3 in Haemophilus influenzae strains, their phenotypic detection and impact on resistance to beta-lactams.
    J Antimicrob Chemother. 2025;80:980-987.
    >> Share

  185. MACGOWAN AP, Griffin P, Attwood MLG, Daum AM, et al
    The pharmacodynamics of fosfomycin in combination with meropenem against Klebsiella pneumoniae studied in an in vitro model of infection.
    J Antimicrob Chemother. 2025;80:967-975.
    >> Share

  186. REBELO AR, Bortolaia V, Leekitcharoenphon P, Hansen DS, et al
    One day in Denmark: whole-genome sequence-based analysis of Escherichia coli isolates from clinical settings.
    J Antimicrob Chemother. 2025;80:1011-1021.
    >> Share

  187. ZHENG YQ, Li QG, Latge JP, Tang XK, et al
    Potential risk of cross-resistance to voriconazole in HIV/AIDS patients with Talaromyces marneffei infection and the mechanisms of the cross-resistance.
    J Antimicrob Chemother. 2025;80:976-979.
    >> Share

    March 2025
  188. SCHELLENBERG JJ, Adam HJ, Baxter MR, Karlowsky JA, et al
    Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing inva
    J Antimicrob Chemother. 2025 Mar 25:dkaf085. doi: 10.1093.
    >> Share

  189. LANDMAN D, Cherniak M, Gefen O, Michael-Gayego A, et al
    Bactericidal activity of antibiotic combinations against clinical isolates of Enterococcus gallinarum and Enterococcus casseliflavus.
    J Antimicrob Chemother. 2025 Mar 25:dkaf095. doi: 10.1093.
    >> Share

  190. GOMEZ-VILLEGAS SI, Rincon S, Carvajal LP, Matiz-Gonzalez JM, et al
    Validation of a modified rapid test to detect the cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus from bloodstream infections in hospitals from North and Latin America.
    J Antimicrob Chemother. 2025 Mar 24:dkaf093. doi: 10.1093.
    >> Share

  191. MANCINI S, Greiner M, Egli A, Nolte O, et al
    In vitro susceptibility testing of vancomycin-resistant Enterococcus faecium to fosfomycin.
    J Antimicrob Chemother. 2025 Mar 18:dkaf084. doi: 10.1093.
    >> Share

  192. SCHRODER D, Cherdtrakulkiat T, Doanh LH, Golparian D, et al
    Exceedingly high levels of tetracycline resistance in Neisseria gonorrhoeae in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-2024-doxycycline post-exposure prophylaxis will unlikely impact gono
    J Antimicrob Chemother. 2025 Mar 18:dkaf066. doi: 10.1093.
    >> Share

  193. CINTHI M, Coccitto SN, Simoni S, Gherardi G, et al
    The optrA, cfr(D) and vanA genes are co-located on linear plasmids in linezolid- and vancomycin-resistant enterococcal clinical isolates in Italy.
    J Antimicrob Chemother. 2025 Mar 17:dkaf082. doi: 10.1093.
    >> Share

  194. MORRISSEY CO
    Diagnosis and management of invasive fungal infections due to non-Aspergillus moulds.
    J Antimicrob Chemother. 2025;80.
    >> Share

  195. PAGANO L, Fernandez OM
    Clinical aspects and recent advances in fungal diseases impacting human health.
    J Antimicrob Chemother. 2025;80.
    >> Share

  196. DONOVAN FM, Fernandez OM, Bains G, DiPompo L, et al
    Coccidioidomycosis: a growing global concern.
    J Antimicrob Chemother. 2025;80.
    >> Share

  197. ARENDRUP MC, Cordonnier C
    Refractory versus resistant invasive aspergillosis.
    J Antimicrob Chemother. 2025;80.
    >> Share

  198. WU S, Zhang L, Luo X, Lin C, et al
    In vitro and in vivo antibacterial activity, resistance analysis and molecular docking study of pleuromutilin derivatives against Streptococcus suis.
    J Antimicrob Chemother. 2025 Mar 13:dkaf064. doi: 10.1093.
    >> Share

  199. LIU Q, Zhou X, Du Z, Wang X, et al
    Intraventricular injection of eravacycline in the treatment of carbapenem-resistant Acinetobacter baumannii meningitis: a case report.
    J Antimicrob Chemother. 2025 Mar 11:dkaf069. doi: 10.1093.
    >> Share

  200. LEE SO, Lee S, Park S, Lee JE, et al
    In vivo evaluation of cefazolin inoculum effect in the treatment of experimental Staphylococcus aureus pneumonia with cefazolin.
    J Antimicrob Chemother. 2025 Mar 4:dkaf065. doi: 10.1093.
    >> Share

  201. DING J, Hameed HMA, Long L, Zhang J, et al
    Correlation between rrs gene mutations and amikacin resistance in Mycobacterium abscessus: implications for fitness cost and clinical prevalence.
    J Antimicrob Chemother. 2025;80:746-751.
    >> Share

  202. CLAUS BOM, De Smedt D, De Cock PA
    Therapeutic drug monitoring versus Bayesian AUC-based dosing for vancomycin in routine practice: a cost-benefit analysis.
    J Antimicrob Chemother. 2025;80:857-867.
    >> Share

  203. SAYDAN S, Schwab F, Holstiege J, Batzing J, et al
    Surveillance of Clostridioides difficile on hospital admission and outpatient antibiotic use in Germany-a 9 year ecological analysis.
    J Antimicrob Chemother. 2025;80:817-824.
    >> Share

  204. KARADOGAN E, Sertcelik A, Dizman GT, Uzar H, et al
    A scoring system to predict resistance to ceftolozane/tazobactam in respiratory isolates of Pseudomonas aeruginosa.
    J Antimicrob Chemother. 2025;80:788-796.
    >> Share

  205. CASTILLO-POLO JA, Hernandez-Garcia M, Maruri-Aransolo A, Morosini MI, et al
    Cefiderocol AST in a real-life Klebsiella pneumoniae collection: challenges in the ATU range.
    J Antimicrob Chemother. 2025;80:797-801.
    >> Share

  206. VAN DEN BERG S, Attwood MGL, Griffin P, Sassen SDT, et al
    Pharmacodynamics of NOSO-502 studied in vitro and in vivo: determination of the dominant pharmacodynamic index driver.
    J Antimicrob Chemother. 2025;80:752-759.
    >> Share

  207. CHIUSAROLI L, Barbieri E, Dell'Anna L, Petris MG, et al
    Efficacy and safety of posaconazole and liposomal amphotericin B use for prophylaxis of invasive fungal infections in a paediatric and young adult haemato-oncological population.
    J Antimicrob Chemother. 2025;80:802-809.
    >> Share

  208. NGUYEN MH, Calado Nogueira de Moura V, Keepers TR, van Ingen J, et al
    In vitro susceptibility of 147 international clinical Mycobacterium abscessus isolates to epetraborole and comparators by broth microdilution.
    J Antimicrob Chemother. 2025;80:713-716.
    >> Share

  209. FAROOQ A, Martens M, Kroemer N, Pfaffendorf C, et al
    Pharmacokinetic/pharmacodynamic analysis of meropenem and fosfomycin combinations in in vitro time-kill and hollow-fibre infection models against multidrug-resistant and carbapenemase-producing Klebsiella pneumoniae.
    J Antimicrob Chemother. 2025;80:701-712.
    >> Share

  210. HARVEY E, Clegg J, Bresnik M, Blatt E, et al
    Development of a novel patient-reported outcome measure for disseminated coccidioidomycosis (valley fever).
    J Antimicrob Chemother. 2025;80:657-665.
    >> Share

  211. TOBIN LA, Abu Sabah E, Lebreton F, Myers GSA, et al
    Genomic analysis of early ST32 Acinetobacter baumannii strains recovered in US military treatment facilities reveals distinct lineages and links to the origins of the Tn6168 ampC transposon.
    J Antimicrob Chemother. 2025;80:666-675.
    >> Share

  212. MUSHTAQ S, Vickers A, Doumith M, Garello P, et al
    Frequencies and mechanisms of mutational resistance to ceftibuten/avibactam in Enterobacterales.
    J Antimicrob Chemother. 2025;80:645-656.
    >> Share

    February 2025
  213. BABIN P, Delbove A, Gousseff M, Gouin JB, et al
    Impact of a kidney-sparing protocol for the treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections (CLOXECO): a quasi-experimental study.
    J Antimicrob Chemother. 2025 Feb 28:dkaf062. doi: 10.1093.
    >> Share

  214. SERAPIDE F, Serraino R, Spadafora L, Bernardi M, et al
    Clinical characteristics, therapy and outcome of bloodstream infections caused by vancomycin-resistant enterococci: a multicentre clinical experience.
    J Antimicrob Chemother. 2025 Feb 25:dkaf055. doi: 10.1093.
    >> Share

  215. PIMENTEL LR, Lucini F, Silva GAD, Simionatto S, et al
    Repurposing tafenoquine as a potent antifungal agent against Candida haemulonii sensu stricto.
    J Antimicrob Chemother. 2025 Feb 24:dkaf054. doi: 10.1093.
    >> Share

  216. LODHIA Z, Costa Da Silva J, Correia C, Cordeiro D, et al
    Surveying genetic markers of antibiotic resistance and genomic background in Chlamydia trachomatis: insights from a multiplex NGS-based approach in clinical strains from Portugal.
    J Antimicrob Chemother. 2025 Feb 17:dkaf036. doi: 10.1093.
    >> Share

  217. LIU W, Xu N, Li W, Mak WY, et al
    Pharmacokinetics and safety of rifapentine in children: dosing for latent tuberculosis infection.
    J Antimicrob Chemother. 2025 Feb 13:dkaf029. doi: 10.1093.
    >> Share

  218. WERTH BJ, Zhang R, Barreras Beltran IA, Penewit K, et al
    Simulated exposures of oritavancin in in vitro pharmacodynamic models select for methicillin-resistant Staphylococcus aureus with reduced susceptibility to oritavancin but minimal cross-resistance or seesaw effect with other antimicrobials.
    J Antimicrob Chemother. 2025 Feb 12:dkaf042. doi: 10.1093.
    >> Share

  219. EDSLEV SM, Aarris M, Nielsen KL, Hertz FB, et al
    rpoB mutations and their association with rifampicin resistance in clinical Staphylococcus epidermidis.
    J Antimicrob Chemother. 2025 Feb 6:dkaf035. doi: 10.1093.
    >> Share

  220. XING H, Zhang L, Li C, Schwarz S, et al
    Identification of a mepR mutation associated with tigecycline resistance in a clinical Staphylococcus aureus isolate.
    J Antimicrob Chemother. 2025 Feb 6:dkaf034. doi: 10.1093.
    >> Share

  221. DE ANTONIO-CUSCO M, Sorli L, Munoz-Bermudez R, Lopez-Mula C, et al
    Penetration of linezolid into the pleural cavity in critically ill patients with proven or suspected Gram-positive bacterial infections: a retrospective pharmacokinetic study.
    J Antimicrob Chemother. 2025;80:554-562.
    >> Share

  222. BROUSSE X, Andry F, Lahouati M, Desmoulin A, et al
    Temocillin efficacy against AmpC beta-lactamase-producing Enterobacterales: a relevant alternative to cefepime?
    J Antimicrob Chemother. 2025;80:576-582.
    >> Share

  223. BIANCO G, Boattini M, Lupo L, Ambretti S, et al
    In vitro activity and genomic characterization of KPC-producing Klebsiella pneumoniae clinical blood culture isolates resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam: an Italian nationwide multicentre observational study
    J Antimicrob Chemother. 2025;80:583-592.
    >> Share

  224. GOLPARIAN D, Rapp E, Hasmats J, Unemo M, et al
    Novel approach using automated target enrichment enables culture-independent accurate whole-genome sequencing of Neisseria gonorrhoeae directly from clinical urogenital and extragenital specimens.
    J Antimicrob Chemother. 2025;80:563-566.
    >> Share

  225. FRATONI AJ, Padgett AM, Roenfanz HF, Duffy EM, et al
    Development and confirmation of humanized plasma and epithelial lining fluid exposures of meropenem, cefiderocol and tobramycin in a standardized neutropenic murine pneumonia model.
    J Antimicrob Chemother. 2025;80:478-484.
    >> Share

  226. JO J, Kim SJ, Kwon KT, Ko KS, et al
    Resilience of tigecycline heteroresistance phenotype in Acinetobacter baumannii.
    J Antimicrob Chemother. 2025;80:496-502.
    >> Share

  227. HAENNI M, Chatre P, Drapeau A, Cazeau G, et al
    Distinct molecular epidemiology of resistances to extended-spectrum cephalosporins and carbapenems in Enterobacter hormaechei in cats and dogs versus horses in France.
    J Antimicrob Chemother. 2025;80:567-575.
    >> Share

  228. IGARASHI Y, Taguchi K, Enoki Y, Chuang VTG, et al
    Simulated achievement rate of beta-lactams/nacubactam treatment in humans using instantaneous MIC-based PK/PD analysis.
    J Antimicrob Chemother. 2025;80:547-553.
    >> Share

  229. CUI XD, Liu SB, Wang RY, He DD, et al
    Investigation on the reversal effect of closantel on colistin resistance in MCR-1 positive Escherichia coli based on dose-response relationship.
    J Antimicrob Chemother. 2025;80:528-537.
    >> Share

  230. OSBORN MR, Zuniga-Moya JC, Mazi PB, Rauseo AM, et al
    Side effects associated with itraconazole therapy.
    J Antimicrob Chemother. 2025;80:503-508.
    >> Share

  231. KOSTOULIAS X, Fu Y, Morris FC, Yu C, et al
    Ceftolozane/tazobactam disrupts Pseudomonas aeruginosa biofilms under static and dynamic conditions.
    J Antimicrob Chemother. 2025;80:372-380.
    >> Share

  232. HUNTER CJ, Marhoffer EA, Holleck JL, Ein Alshaeba S, et al
    Effect of empiric antibiotics against Pseudomonas aeruginosa on mortality in hospitalized patients: a systematic review and meta-analysis.
    J Antimicrob Chemother. 2025;80:322-333.
    >> Share

  233. HOFKEN LM, Schauer J, Eisfeld J, Dziobaka J, et al
    Characterization of NWM-1, a novel subclass B3 metallo-beta-lactamase found in a clinical isolate of Pseudomonas aeruginosa.
    J Antimicrob Chemother. 2025;80:445-451.
    >> Share

  234. TUMBARELLO M, Giuliano G, Criscuolo M, Del Principe MI, et al
    Clinical impact of ceftazidime/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study.
    J Antimicrob Chemother. 2025;80:386-398.
    >> Share

    January 2025
  235. ABDOLRASOULI A, Curtis CM, Spruijtenburg B, Flores A, et al
    Cluster of clonal fluconazole-resistant Candida parapsilosis harbouring Y132F mutation in ERG11 gene in a neonatal ICU in the UK.
    J Antimicrob Chemother. 2025 Jan 29:dkaf015. doi: 10.1093.
    >> Share

  236. DRONEY M, Reed E, Sarwar S, Coe K, et al
    Fluconazole step-down therapy versus echinocandins for the treatment of Candida glabrata invasive candidiasis with candidaemia.
    J Antimicrob Chemother. 2025 Jan 28:dkaf026. doi: 10.1093.
    >> Share

  237. BITTERMAN R, Awwad A, Darawsha B, Dallashi H, et al
    Ceftaroline versus vancomycin for methicillin-resistant Staphylococcus aureus bacteraemia, a matched cohort study.
    J Antimicrob Chemother. 2025 Jan 28:dkaf009. doi: 10.1093.
    >> Share

  238. CADDEY B, Shaukat W, Tang KL, Barkema HW, et al
    Vancomycin-resistant Enterococcus prevalence and its association along the food chain: a systematic review and meta-analysis.
    J Antimicrob Chemother. 2025 Jan 24:dkaf008. doi: 10.1093.
    >> Share

  239. YANXIA S, Xuewei W, Gang L, Wei J, et al
    Analysis on characteristics and multilocus sequence typing of Clostridium perfringens in western China.
    J Antimicrob Chemother. 2025;80:216-226.
    >> Share

  240. ANDES D, Bruggemann RJ, Flanagan S, Lepak AJ, et al
    The distinctive pharmacokinetic profile of rezafungin, a long-acting echinocandin developed in the era of modern pharmacometrics.
    J Antimicrob Chemother. 2025;80:18-28.
    >> Share

  241. BILBAO I, Pineda Abel de la Cruz I, de Asis Carmona-Torre F, Rodriguez-Mateos M, et al
    Use of echinocandins combined with clindamycin in Pneumocystis pneumonia: a case series of 14 patients.
    J Antimicrob Chemother. 2025;80:102-105.
    >> Share

  242. CHEN S, Shang Y, Zheng J, Huo F, et al
    In vitro monitoring of drug resistance emergence during stepwise induction of bedaquiline and clofazimine, alone and in combination: a phenotypic and genotypic analysis.
    J Antimicrob Chemother. 2025;80:262-269.
    >> Share

  243. ROGER PM, Strzelecki AC, Dautezac V, Hennet MA, et al
    Diagnostic uncertainties in patients with bacteraemia: impact on antibiotic prescriptions and outcome.
    J Antimicrob Chemother. 2025;80:238-246.
    >> Share

  244. BALTAS I, Patel T, Soares AL
    Resistance profiles of carbapenemase-producing Enterobacterales in a large centre in England: are we already losing cefiderocol?
    J Antimicrob Chemother. 2025;80:59-67.
    >> Share

  245. HIRABAYASHI A, Yano H, Yahara K, Aoki S, et al
    Emergence of the mobile RND-type efflux pump gene cluster tmexCD1-toprJ1 in Klebsiella pneumoniae clinical isolates in Japan.
    J Antimicrob Chemother. 2025;80:192-199.
    >> Share

  246. ANDO N, Mizushima D, Takano M, Mitobe M, et al
    Prolonged sitafloxacin and doxycycline combination regimen for treating infections by highly resistant Mycoplasma genitalium.
    J Antimicrob Chemother. 2025;80:247-253.
    >> Share

  247. LONG H, Zhao F, Feng Y, Zong Z, et al
    Global emergence of Escherichia coli with PBP3 insertions.
    J Antimicrob Chemother. 2025;80:178-181.
    >> Share

  248. FRATONI AJ, Padgett AM, Duffy EM, Nicolau DP, et al
    Establishment of a diverse pheno-genotypic challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa suitable for use in the murine pneumonia model.
    J Antimicrob Chemother. 2025;80:154-161.
    >> Share

  249. ISHAK A, Mazonakis N, Spernovasilis N, Akinosoglou K, et al
    Bactericidal versus bacteriostatic antibacterials: clinical significance, differences and synergistic potential in clinical practice.
    J Antimicrob Chemother. 2025;80:1-17.
    >> Share

  250. PARIONA JGM, Vasquez-Ponce F, Pariona EMM, Sousa-Carmo RR, et al
    Efficacy of meropenem against ceftazidime-avibactam-resistant Klebsiella pneumoniae producing KPC-31, KPC-33, KPC-90, KPC-106 and KPC-114.
    J Antimicrob Chemother. 2025;80:162-168.
    >> Share

  251. O'JEANSON A, Nielsen EI, Friberg LE
    Therapeutic drug monitoring (TDM) of beta-lactam/beta-lactamase inhibitor (BL/BLI) drug combinations: insights from a pharmacometric simulation study.
    J Antimicrob Chemother. 2025;80:79-86.
    >> Share

    December 2024
  252. KIM SH, Kim HM, Chung DR, Ko JH, et al
    Synergistic effects of colistin-rifampin-based triple antimicrobial combination therapy against Carbapenem-resistant Pseudomonas aeruginosa: a time-kill assay.
    J Antimicrob Chemother. 2024 Dec 31:dkae466. doi: 10.1093.
    >> Share

  253. KUO CF, Chen YY, Chiu CC, Chiu CW, et al
    Comparative in vitro efficacy of AR-12 derivatives against Streptococcus pyogenes.
    J Antimicrob Chemother. 2024 Dec 20:dkae462. doi: 10.1093.
    >> Share

  254. ERSOY SC, Madrigal SL, Proctor RA, Chambers HF, et al
    NaHCO3 modulates the bla operon and beta-lactam susceptibility in borderline oxacillin-resistant Staphylococcus aureus (BORSA).
    J Antimicrob Chemother. 2024 Dec 20:dkae455. doi: 10.1093.
    >> Share

  255. HANAI Y, Matsumoto K, Endo A, Hanawa K, et al
    Treatment success prediction in patients with methicillin-resistant coagulase-negative staphylococci infections, using vancomycin AUC24/MIC ratio: a multicentre retrospective cohort study.
    J Antimicrob Chemother. 2024 Dec 17:dkae442. doi: 10.1093.
    >> Share

  256. ASSEFA GM, Roberts JA, Aslan AT, Mohammed SA, et al
    A systematic review and individual bacterial species level meta-analysis of in vitro studies on the efficacy of ceftazidime/avibactam combined with other antimicrobials against carbapenem-resistant Gram-negative bacteria.
    J Antimicrob Chemother. 2024 Dec 17:dkae451. doi: 10.1093.
    >> Share

  257. ZHANG G, Luo Z, Yang Q, Kang W, et al
    Establishment of epidemiological cut-off values of etimicin: a new fourth-generation aminoglycoside, against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus.
    J Antimicrob Chemother. 2024 Dec 9:dkae414. doi: 10.1093.
    >> Share

  258. LI X, Qi X, Wang B, Fu L, et al
    Efficacy of nintedanib as a host-directed therapy candidate in the treatment of tuberculosis.
    J Antimicrob Chemother. 2024 Dec 4:dkae429. doi: 10.1093.
    >> Share

  259. DOELMAN TA, Adriaens N, Westerhuis BM, Bruisten SM, et al
    Phenotypic antibiotic resistance of Mycoplasma genitalium and its variation between different macrolide resistance-associated mutations.
    J Antimicrob Chemother. 2024 Dec 4:dkae430. doi: 10.1093.
    >> Share

  260. WEERDENBURG H, Gwee A, Haeusler GM, Osowicki J, et al
    Crushed posaconazole delayed-release tablets for antifungal prophylaxis and treatment in children.
    J Antimicrob Chemother. 2024;79:3340-3343.
    >> Share

  261. GAO Y, Wu T, Pu L, Ji X, et al
    Identification of vancomycin exposure target in neonates: how much is enough?
    J Antimicrob Chemother. 2024;79:3344-3353.
    >> Share

  262. FOUAD A, Nicolau SE, Tamma PD, Simner PJ, et al
    Differential frequency of persister cells in clinically derived isolates of Pseudomonas aeruginosa after exposure to cefiderocol and ceftolozane/tazobactam.
    J Antimicrob Chemother. 2024;79:3236-3242.
    >> Share

  263. GODRON AS, Amoura A, Pistien C, Birgy A, et al
    Inoculum effect of cefiderocol against NDM-1 producing Escherichia coli in vitro and in a murine model of peritonitis.
    J Antimicrob Chemother. 2024;79:3323-3331.
    >> Share

  264. FRATONI AJ, Padgett AM, Duffy EM, Nicolau DP, et al
    Quantitative performance of humanized serum and epithelial lining fluid exposures of tigecycline and levofloxacin against a challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa in a standardized neutropenic murine pneumonia model.
    J Antimicrob Chemother. 2024;79:3142-3149.
    >> Share

  265. FIFER H, Doumith M, Rubinstein L, Mitchell L, et al
    Ceftriaxone-resistant Neisseria gonorrhoeae detected in England, 2015-24: an observational analysis.
    J Antimicrob Chemother. 2024;79:3332-3339.
    >> Share

  266. PARDOS SL, Hope W, Kotsaki A, Das S, et al
    Population pharmacokinetics/pharmacodynamics of minocycline plus rifampicin in patients with complicated skin and skin structure infections caused by MRSA.
    J Antimicrob Chemother. 2024;79:3303-3312.
    >> Share

  267. QUINONES-VICO MI, Andrades-Amate M, Fernandez-Gonzalez A, Ubago-Rodriguez A, et al
    Antibiotic biocompatibility assay and anti-biofilm strategies for Pseudomonas aeruginosa infection in bioengineered artificial skin substitutes.
    J Antimicrob Chemother. 2024;79:3313-3322.
    >> Share

  268. STERN A, Henig I, Cohen M, Gur I, et al
    Impact of discontinuing routine fluoroquinolone prophylaxis in neutropenic allogeneic haematopoietic stem cell transplant recipients: an observational study.
    J Antimicrob Chemother. 2024;79:3289-3296.
    >> Share

  269. STEMKENS R, Lemson A, Koele SE, Svensson EM, et al
    A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease.
    J Antimicrob Chemother. 2024;79:3100-3108.
    >> Share

  270. HUANG Y, Liao M, Hu X, Hu H, et al
    Advances in the clinical treatment of multidrug-resistant pathogens using polymyxins.
    J Antimicrob Chemother. 2024;79:3210-3229.
    >> Share

  271. ZOHAR I, Ben David D, Schwartz O, Pomerantz A, et al
    Amikacin treatment in patients with Enterobacterales bacteraemia: impact of MIC on mortality.
    J Antimicrob Chemother. 2024;79:3204-3209.
    >> Share

  272. VANPARIS O, Oueslati S, Girlich D, Jousset AB, et al
    Genetic and biochemical characterization of OXA-1186, a novel OXA-198-type carbapenemase hydrolysing cephalosporins in Citrobacter freundii.
    J Antimicrob Chemother. 2024;79:3186-3190.
    >> Share

  273. ALVAREZ C, Nastro M, Goyheneche B, Potente N, et al
    NDM-5-producing Klebsiella pneumoniae ST258 in a university hospital in Argentina.
    J Antimicrob Chemother. 2024;79:3174-3177.
    >> Share

  274. MUDDE SE, Meliefste HM, Ammerman NC, de Steenwinkel JEM, et al
    Mycobacterium abscessus strain variability in preclinical drug development: does it really matter?
    J Antimicrob Chemother. 2024;79:3169-3173.
    >> Share

    November 2024
  275. LEROY AG, Lemenand O, Thibaut S, Coeffic T, et al
    Assessment of co-resistance to antibiotics recommended for acute pyelonephritis among Escherichia coli clinical strains from community- and nursing home-acquired urinary tract infections.
    J Antimicrob Chemother. 2024 Nov 29:dkae431. doi: 10.1093.
    >> Share

  276. LIU Q, Li S, Wang X, Lin Y, et al
    Comparative evaluation of eravacycline susceptibility testing methods in 587 clinical carbapenem-resistant Acinetobacter baumannii isolates: broth microdilution, MIC test strip and disc diffusion.
    J Antimicrob Chemother. 2024 Nov 21:dkae426. doi: 10.1093.
    >> Share

  277. HERNANDEZ-LOZANO I, Aranzana-Climent V, Cao S, Matias C, et al
    Model-informed drug development for antimicrobials: translational pharmacokinetic-pharmacodynamic modelling of apramycin to facilitate prediction of efficacious dose in complicated urinary tract infections.
    J Antimicrob Chemother. 2024 Nov 16:dkae409. doi: 10.1093.
    >> Share

  278. MCGUIRE E, Ready D, Ellaby N, Potterill I, et al
    A case of penicillin-resistant group B Streptococcus isolated from a patient in the UK.
    J Antimicrob Chemother. 2024 Nov 15:dkae419. doi: 10.1093.
    >> Share

  279. RAGUNATHAN P, Sae-Lao P, Harikishore A, Daher W, et al
    SQ31f is a potent non-tuberculous mycobacteria antibiotic by specifically targeting the mycobacterial F-ATP synthase.
    J Antimicrob Chemother. 2024 Nov 5:dkae406. doi: 10.1093.
    >> Share

  280. AGIBOTHU KUPPARAM HK, Shah I, Chandrasekaran P, Mane S, et al
    Pharmacokinetics of anti-TB drugs in children and adolescents with drug-resistant TB: a multicentre observational study from India.
    J Antimicrob Chemother. 2024;79:2939-2947.
    >> Share

  281. COMCE MH, Weersink RA, Beuers U, van Hest RM, et al
    Pharmacokinetics of ceftriaxone, gentamicin, meropenem and vancomycin in liver cirrhosis: a systematic review.
    J Antimicrob Chemother. 2024;79:2750-2761.
    >> Share

  282. BLOUIN K, Lefebvre B, Trudelle A, Defay F, et al
    Neisseria gonorrhoeae treatment failure to the recommended antibiotic regimen-Quebec, Canada, 2015-19.
    J Antimicrob Chemother. 2024;79:3029-3040.
    >> Share

  283. QIAN C, Hu P, Guo W, Han Y, et al
    Genome analysis of tigecycline-resistant Acinetobacter baumannii reveals nosocomial lineage shifts and novel resistance mechanisms.
    J Antimicrob Chemother. 2024;79:2965-2974.
    >> Share

  284. LODISE TP, Obi EN, Watanabe AH, Yucel E, et al
    Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa.
    J Antimicrob Chemother. 2024;79:2954-2964.
    >> Share

  285. DUKE C, Parker SL, Zam BB, Chiong F, et al
    Population pharmacokinetics of unbound cefazolin in infected hospitalized patients requiring intermittent high-flux haemodialysis: can a three-times-weekly post-dialysis dosing regimen provide optimal treatment?
    J Antimicrob Chemother. 2024;79:2980-2989.
    >> Share

  286. SANDOE JAT, Grozeva D, Albur M, Bond SE, et al
    A retrospective propensity-score-matched cohort study of the impact of procalcitonin testing on antibiotic use in hospitalized patients during the first wave of COVID-19.
    J Antimicrob Chemother. 2024;79:2792-2800.
    >> Share

  287. SHUKLA A, Rodriguez S, Brennan-Krohn T
    Activity of antibiotics against Burkholderia cepacia complex in artificial sputum medium.
    J Antimicrob Chemother. 2024;79:2867-2876.
    >> Share

  288. VENA A, Schenone M, Corcione S, Giannella M, et al
    Impact of adequate empirical combination therapy on mortality in septic shock due to Pseudomonas aeruginosa bloodstream infections: a multicentre retrospective cohort study.
    J Antimicrob Chemother. 2024;79:2846-2853.
    >> Share

  289. MA P, Shang S, Liu R, Dong Y, et al
    Prediction of teicoplanin plasma concentration in critically ill patients: a combination of machine learning and population pharmacokinetics.
    J Antimicrob Chemother. 2024;79:2815-2827.
    >> Share

  290. YANG F, Sun X, Fu Y, Zhao F, et al
    High-level ceftriaxone resistance due to transfer of penA allele 60.001 into endemic gonococcal lineages in Hangzhou, China.
    J Antimicrob Chemother. 2024;79:2854-2857.
    >> Share

  291. COJUTTI PG, Pai MP, Gatti M, Rinaldi M, et al
    An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in cri
    J Antimicrob Chemother. 2024;79:2801-2808.
    >> Share

  292. LONGO BM, Trunfio M, Calcagno A
    Dual beta-lactams for the treatment of Mycobacterium abscessus: a review of the evidence and a call to act against an antibiotic nightmare.
    J Antimicrob Chemother. 2024;79:2731-2741.
    >> Share

    October 2024
  293. AVCU G, Erci E, Bilen NM, Ersayoglu I, et al
    Clinical outcomes and the impact of treatment modalities in children with carbapenem-resistant Enterobacteriaceae bloodstream infections: a retrospective cohort study from a tertiary university hospital.
    J Antimicrob Chemother. 2024 Oct 30:dkae387. doi: 10.1093.
    >> Share

  294. STURARO MC, de Souza GHA, Damaceno NDS, Silva ON, et al
    Antimicrobial activity of ceftibuten/polymyxin B combination against polymyxin/carbapenem-resistant Klebsiella pneumoniae.
    J Antimicrob Chemother. 2024 Oct 25:dkae382. doi: 10.1093.
    >> Share

  295. GHAHRAMANI A, Naghadian Moghaddam MM, Kianparsa J, Ahmadi MH, et al
    Overall status of carbapenem resistance among clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis.
    J Antimicrob Chemother. 2024 Oct 11:dkae358. doi: 10.1093.
    >> Share

  296. GACHET B, Dechartres A, Senneville E, Robineau O, et al
    Systematic review on oral antibacterial relay therapy for acute staphylococcal prosthetic joint infections treated with debridement, antibiotics and implant retention (DAIR).
    J Antimicrob Chemother. 2024 Oct 9:dkae347. doi: 10.1093.
    >> Share

  297. YU L, Han X, Zhang W, Fu Y, et al
    The two-component sensor factor envZ influences antibiotic resistance and virulence in the evolutionary dynamics of multidrug-resistant Salmonella enteritidis causing multisite invasive infections.
    J Antimicrob Chemother. 2024 Oct 4:dkae355. doi: 10.1093.
    >> Share

  298. PATAMATAMKUL S
    Comment on: Carbapenem combination therapy versus standard of care for persistent methicillin-susceptible Staphylococcus aureus bacteraemia.
    J Antimicrob Chemother. 2024 Oct 1:dkae353. doi: 10.1093.
    >> Share

  299. COCCITTO SN, Massacci FR, Cinthi M, Albini E, et al
    Novel optrA-carrying integrative and conjugative element in a porcine Streptococcus suis, Italy.
    J Antimicrob Chemother. 2024 Oct 1:dkae354. doi: 10.1093.
    >> Share

  300. ESCRIHUELA-VIDAL F, Fernandez-Hidalgo N, Munoz P, Villamarin M, et al
    Infective endocarditis caused by penicillin-resistant viridans group streptococci: a series of nine cases from a Spanish cohort.
    J Antimicrob Chemother. 2024 Oct 1:dkae345. doi: 10.1093.
    >> Share

  301. BUTLER DA, Patel N, O'Donnell JN, Lodise TP, et al
    Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature.
    J Antimicrob Chemother. 2024;79:2421-2459.
    >> Share

  302. ALIEVA KN, Golikova MV, Zinner SH
    Role of volume and inoculum in MIC assessment: a study with meropenem and Klebsiella pneumoniae.
    J Antimicrob Chemother. 2024;79:2698-2707.
    >> Share

  303. AZAMGARHI T, Scarborough M, Peter-Akhigbe V, Scobie A, et al
    Fluoroquinolones in orthopaedic infection: balancing risks and rewards.
    J Antimicrob Chemother. 2024;79:2413-2416.
    >> Share

  304. MASSIP C, Feletti L, Chagneau CV, Dumont Y, et al
    Evaluation of several routine methods for fosfomycin and mecillinam susceptibility testing of Enterobacterales urine isolates.
    J Antimicrob Chemother. 2024;79:2645-2652.
    >> Share

  305. DU B, Zhang W, Wang Y, Wu YE, et al
    Optimal dosing regimen of caspofungin in adolescents with allogeneic haematopoietic stem cell transplantation.
    J Antimicrob Chemother. 2024;79:2678-2687.
    >> Share

  306. HALLIDAY CL, Tay E, Green W, Law D, et al
    In vitro activity of olorofim against 507 filamentous fungi including antifungal drug-resistant strains at a tertiary laboratory in Australia: 2020-2023.
    J Antimicrob Chemother. 2024;79:2611-2621.
    >> Share

  307. CHAFTARI AM, Dagher H, Hachem R, Jiang Y, et al
    A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia.
    J Antimicrob Chemother. 2024;79:2543-2553.
    >> Share

  308. GATTI M, Rinaldi M, Laici C, Ambretti S, et al
    Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in a case series of orthotopic liver transplant recipients.
    J Antimicrob Chemother. 2024;79:2586-2590.
    >> Share

  309. SEKIGUCHI WK, de Oliveira VF, Cavassin FB, Taborda M, et al
    A multicentre study of amphotericin B treatment for histoplasmosis: assessing mortality rates and adverse events.
    J Antimicrob Chemother. 2024;79:2598-2606.
    >> Share

  310. DAVIN-REGLI A, Pages JM, Vergalli J
    The contribution of porins to enterobacterial drug resistance.
    J Antimicrob Chemother. 2024;79:2460-2470.
    >> Share

  311. ZHANG XW, Song JJ, Zeng SH, Huang YL, et al
    Plasmid-mediated azithromycin resistance in non-typhoidal Salmonella recovered from human infections.
    J Antimicrob Chemother. 2024;79:2688-2697.
    >> Share

  312. LIN YJ, Zou Y, Karlsson MO, Svensson EM, et al
    A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB.
    J Antimicrob Chemother. 2024;79:2561-2569.
    >> Share

  313. GONZALEZ-PINTO L, Alonso-Garcia I, Blanco-Martin T, Camacho-Zamora P, et al
    Impact of chromosomally encoded resistance mechanisms and transferable beta-lactamases on the activity of cefiderocol and innovative beta-lactam/beta-lactamase inhibitor combinations against Pseudomonas aeruginosa.
    J Antimicrob Chemother. 2024;79:2591-2597.
    >> Share

  314. VAN OS W, Nussbaumer-Proll A, Pham AD, Wijnant GJ, et al
    Pharmacokinetic/pharmacodynamic model-based optimization of temocillin dosing strategies for the treatment of systemic infections.
    J Antimicrob Chemother. 2024;79:2484-2492.
    >> Share

  315. HARRYVAN TJ, Schaftenaar E, Franssens BT, Melles DC, et al
    EUCAST ciprofloxacin area of technical uncertainty in Escherichia coli and Klebsiella pneumoniae using BD Phoenix and VITEK(R) 2 automated susceptibility systems.
    J Antimicrob Chemother. 2024;79:2718-2719.
    >> Share

    September 2024
  316. SHAN X, Li C, Zhang L, Zou C, et al
    poxtA amplification and mutations in 23S rRNA confer enhanced linezolid resistance in Enterococcus faecalis.
    J Antimicrob Chemother. 2024 Sep 27:dkae342. doi: 10.1093.
    >> Share

  317. YANG W, Li X, Chen J, Zhang G, et al
    Multicentre evaluation of in vitro activity of contezolid against drug-resistant Staphylococcus and Enterococcus.
    J Antimicrob Chemother. 2024 Sep 24:dkae331. doi: 10.1093.
    >> Share

  318. SAPORTA R, Nielsen EI, Menetrey A, Cameron DR, et al
    Model-based translation of results from in vitro to in vivo experiments for afabicin activity against Staphylococcus aureus.
    J Antimicrob Chemother. 2024 Sep 24:dkae334. doi: 10.1093.
    >> Share

  319. FRENS J, Baumeister T, Sinclair E, Zeigler D, et al
    Getting rapid diagnostic test data into the appropriate hands by leveraging pharmacy staff and a clinical surveillance platform: a case study from a US community hospital.
    J Antimicrob Chemother. 2024;79.
    >> Share

  320. YUCEEL-TIMUR I, Thierry E, Chainier D, Ndao I, et al
    Retrospective evaluation of rapid genotypic ID and phenotypic AST systems on positive blood culture turnaround time and simulated potential impacts on bloodstream infection management.
    J Antimicrob Chemother. 2024;79.
    >> Share

  321. FITTS EC, Dent EA, Burd EM
    Validation of short culture method for rapid bacterial identification of blood cultures via matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    J Antimicrob Chemother. 2024;79.
    >> Share

  322. MACVANE SH, Dwivedi HP
    Evaluating the impact of rapid antimicrobial susceptibility testing for bloodstream infections: a review of actionability, antibiotic use and patient outcome metrics.
    J Antimicrob Chemother. 2024;79.
    >> Share

  323. SLAVIN M, Johnson A
    JAC Supplement: 'faster ID and AST revolution: how to improve antibiotic use in the critically ill'.
    J Antimicrob Chemother. 2024;79.
    >> Share

  324. KARLOWSKY JA, Wise MG, Hackel MA, Six DA, et al
    Cefepime-taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018-22.
    J Antimicrob Chemother. 2024 Sep 17:dkae329. doi: 10.1093.
    >> Share

  325. KRUGER-HAKER H, Kostova V, Hanke D, Kaspar H, et al
    Genetic basis of macrolide resistance in porcine Pasteurella multocida isolates from the German national resistance monitoring program GERM-Vet 2008-2021.
    J Antimicrob Chemother. 2024 Sep 13:dkae316. doi: 10.1093.
    >> Share

  326. CLARKE F, Grenfell A, Chao S, Richards H, et al
    Use of echinocandin outpatient parenteral antimicrobial therapy for the treatment of infection caused by Candida spp.: utilization, outcomes and impact of a change to weekly dosing.
    J Antimicrob Chemother. 2024 Sep 11:dkae302. doi: 10.1093.
    >> Share

  327. ABDELALL LM, Nagy YI, Kashef MT
    Restoring vancomycin activity against resistant Enterococcus faecalis using a transcription factor decoy as a vanA operon-inhibitor.
    J Antimicrob Chemother. 2024 Sep 10:dkae320. doi: 10.1093.
    >> Share

  328. WIDERSTROM R, Aarris M, Jacobsson S, Stegger M, et al
    Probing fosfomycin's potential: a study on susceptibility testing and resistance in Staphylococcus epidermidis from prosthetic joint infections.
    J Antimicrob Chemother. 2024 Sep 6:dkae312. doi: 10.1093.
    >> Share

  329. BOUTZOUKAS AE, Mackow N, Giri A, Komarow L, et al
    Increased mortality in hospital- compared to community-onset carbapenem-resistant enterobacterales infections.
    J Antimicrob Chemother. 2024 Sep 5:dkae306. doi: 10.1093.
    >> Share

  330. MAILLARD A, Froelicher Bournaud L, Pastre J, Planquette B, et al
    Penetration of isavuconazole into the epithelial lining fluid of patients with pulmonary fungal infections. Comment on: 'Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions'
    J Antimicrob Chemother. 2024;79:2403-2405.
    >> Share

  331. ZHOU J, Xu B, Zheng Y, Huang H, et al
    Optimization of oral isavuconazole dose for population in special physiological or pathological state: a physiologically based pharmacokinetics model-informed precision dosing.
    J Antimicrob Chemother. 2024;79:2379-2389.
    >> Share

  332. ABOUELHASSAN Y, Kuti JL, Nicolau DP, Abdelraouf K, et al
    Ampicillin-sulbactam against Acinetobacter baumannii infections: pharmacokinetic/pharmacodynamic appraisal of current susceptibility breakpoints and dosing recommendations.
    J Antimicrob Chemother. 2024;79:2227-2236.
    >> Share

  333. HUANG Y, Cai Z, Lv L, Yue C, et al
    Emergence of mcr-8.1 gene coexisting with blaNDM in Citrobacter werkmanii isolated from a chicken farm in China.
    J Antimicrob Chemother. 2024;79:2392-2394.
    >> Share

  334. BASSETTI M, Cascio A, De Rosa FG, Meschiari M, et al
    Management of Clostridioides difficile infection: an Italian Delphi consensus.
    J Antimicrob Chemother. 2024;79:2103-2118.
    >> Share

  335. FEUER L, Frenzer SK, Merle R, Leistner R, et al
    Prevalence of MRSA in canine and feline clinical samples from one-third of veterinary practices in Germany from 2019-2021.
    J Antimicrob Chemother. 2024;79:2273-2280.
    >> Share

  336. DAVID A, Golparian D, Jacobsson S, Stratton C, et al
    In silico gepotidacin target mining among 33 213 global Neisseria gonorrhoeae genomes from 1928 to 2023 combined with gepotidacin MIC testing of 22 gonococcal isolates with different GyrA and ParC substitutions.
    J Antimicrob Chemother. 2024;79:2221-2226.
    >> Share

  337. JAIDANE N, Vanparis O, Mansour W, Volland H, et al
    Evaluation of a novel lateral flow immunochromatographic assay for the rapid detection of KPC, NDM, IMP, VIM and OXA-48 carbapenemases in Gram-negatives.
    J Antimicrob Chemother. 2024;79:2396-2399.
    >> Share

  338. DIZI ISIK A, Akkoc G, Ergenc Z, Yilmaz S, et al
    The use of fosfomycin in infections caused by multidrug-resistant pathogens, especially pneumonia in children: a five-year retrospective single-centre experience.
    J Antimicrob Chemother. 2024;79:2179-2185.
    >> Share

  339. ARCONADA NUIN E, Vilken T, Xavier BB, Doua J, et al
    A microbiological and genomic perspective of globally collected Escherichia coli from adults hospitalized with invasive E. coli disease.
    J Antimicrob Chemother. 2024;79:2142-2151.
    >> Share

  340. ABOUELHASSAN Y, Nicolau DP, Abdelraouf K
    Defining optimal sulbactam regimens for treatment of Acinetobacter baumannii pneumonia and impact of blaOXA-23 on efficacy.
    J Antimicrob Chemother. 2024;79:2306-2316.
    >> Share

  341. CHEN H, Zhou X, Dai W
    Identification of antimicrobial-susceptible Pseudomonas aeruginosa RpoA variant strains through positional conservation pattern.
    J Antimicrob Chemother. 2024;79:2298-2305.
    >> Share

  342. GUO CG, Jiang F, Li Y, Chen Y, et al
    Real-world efficacy of second-line therapies for Helicobacter pylori: a population-based study.
    J Antimicrob Chemother. 2024;79:2263-2272.
    >> Share

    August 2024
  343. PAPOUSKOVA A, Drabkova Z, Brajerova M, Krutova M, et al
    The circulation of methicillin-resistant Staphylococcus aureus between humans, horses and the environment at the equine clinic.
    J Antimicrob Chemother. 2024 Aug 30:dkae303. doi: 10.1093.
    >> Share

  344. ESCRIHUELA-VIDAL F, Chico C, Borjabad Gonzalez B, Vazquez Sanchez D, et al
    Effect of a bundle intervention on adherence to quality-of-care indicators and on clinical outcomes in patients with Staphylococcus aureus bacteraemia hospitalized in non-referral community hospitals.
    J Antimicrob Chemother. 2024 Aug 30:dkae298. doi: 10.1093.
    >> Share

  345. HACIOGLU M, Yilmaz FN, Yetke HI, Haciosmanoglu-Aldogan E, et al
    Synergistic effects of quorum-sensing molecules and antimicrobials against Candida albicans and Pseudomonas aeruginosa biofilms: in vitro and in vivo studies.
    J Antimicrob Chemother. 2024 Aug 30:dkae293. doi: 10.1093.
    >> Share


  346. Correction to: Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre.
    J Antimicrob Chemother. 2024 Aug 28:dkae317. doi: 10.1093.
    >> Share

  347. VILLAMARIN M, Fernandez-Hidalgo N, Vinado B, Gonzalez-Lopez JJ, et al
    Use of teicoplanin monotherapy for the treatment of enterococcal infective endocarditis: a retrospective and comparative study at a referral centre.
    J Antimicrob Chemother. 2024 Aug 19:dkae291. doi: 10.1093.
    >> Share

  348. LUZARRAGA V, Cremniter J, Plouzeau C, Michaud A, et al
    In vitro activity of delafloxacin against clinical levofloxacin-resistant Helicobacter pylori isolates.
    J Antimicrob Chemother. 2024 Aug 10:dkae269. doi: 10.1093.
    >> Share

  349. WALTER K, Te Brake LHM, Lemm AK, Hoelscher M, et al
    Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures.
    J Antimicrob Chemother. 2024 Aug 7:dkae266. doi: 10.1093.
    >> Share

  350. SCHELLENBERG JJ, Adam HJ, Baxter MR, Karlowsky JA, et al
    Phenotypic and molecular characterization of Streptococcus pneumoniae serotype 3 isolates from blood and respiratory samples in Canada: CANWARD 2007-21.
    J Antimicrob Chemother. 2024 Aug 2:dkae272. doi: 10.1093.
    >> Share

  351. MEIJS AP, Chaname-Pinedo LE, Deng H, Veldman KT, et al
    Association between antimicrobial usage in livestock and antimicrobial resistance in Escherichia coli isolates from human urinary tract infections in the Netherlands, 2009-2020.
    J Antimicrob Chemother. 2024 Aug 2:dkae268. doi: 10.1093.
    >> Share

  352. YANG Q, Li L, Zhao G, Cui Q, et al
    Characterization of a multiresistance optrA- and lsa(E)-harbouring unconventional circularizable structure in Streptococcus suis.
    J Antimicrob Chemother. 2024 Aug 1:dkae250. doi: 10.1093.
    >> Share

  353. MAERTENS J, Slavin M, Hoenigl M, Thompson GR 3rd, et al
    Breaking the mould: challenging the status quo of clinical trial response definitions for invasive fungal diseases-a debate.
    J Antimicrob Chemother. 2024;79:1786-1793.
    >> Share

  354. WIJK M, Gausi K, Malatesta S, Weber SE, et al
    The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs.
    J Antimicrob Chemother. 2024;79:2022-2030.
    >> Share

  355. GAMELL A, Velasco-Arnaiz E, Lopez-Ramos MG, Rios-Barnes M, et al
    Off-label use of dalbavancin in children: a case series.
    J Antimicrob Chemother. 2024;79:2062-2067.
    >> Share

  356. ONG SWX, Luo J, Fridman DJ, Lee SM, et al
    Epidemiology and clinical relevance of persistent bacteraemia in patients with Gram-negative bloodstream infection: a retrospective cohort study.
    J Antimicrob Chemother. 2024;79:2053-2061.
    >> Share

  357. BOUDJELLA-SENHADJI I, Bour M, Potron A, Lorme F, et al
    Cross-transmission of Acinetobacter junii carrying blaOXA-58 in a neonatal ICU.
    J Antimicrob Chemother. 2024;79:1910-1913.
    >> Share

  358. SHAH S, Clarke L, Davis MW, Topal JE, et al
    Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis.
    J Antimicrob Chemother. 2024;79:2017-2021.
    >> Share

  359. DENG L, Lv LC, Tu J, Yue C, et al
    Clonal spread of blaNDM-1-carrying Salmonella enterica serovar Typhimurium clone ST34 and wide spread of IncHI2/ST3-blaNDM-5 plasmid in China.
    J Antimicrob Chemother. 2024;79:1900-1909.
    >> Share

  360. SANCHEZ L, Bitar M, Herail Q, Dorchene D, et al
    In vitro and intracellular activity of vaborbactam combined with beta-lactams against Mycobacterium abscessus.
    J Antimicrob Chemother. 2024;79:1914-1918.
    >> Share

  361. ERGUN M, Jansen AME, Hilbrands LB, de Kort E, et al
    Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study.
    J Antimicrob Chemother. 2024;79:1801-1810.
    >> Share

  362. YANG YS, Chen HY, Lin IC, Lin MH, et al
    Imipenem reduces the efficacy of vancomycin against Elizabethkingia species.
    J Antimicrob Chemother. 2024;79:2048-2052.
    >> Share

  363. UNEMO M, Sanchez-Buso L, Golparian D, Jacobsson S, et al
    The novel 2024 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations and superseded WHO N. gonorrhoeae reference strains-phenotypic, genetic and reference genome characterization.
    J Antimicrob Chemother. 2024;79:1885-1899.
    >> Share

  364. DELAHAYE A, Eldin C, Bleibtreu A, Djossou F, et al
    Treatment of persistent focalized Q fever: time has come for an international randomized controlled trial.
    J Antimicrob Chemother. 2024;79:1725-1747.
    >> Share

  365. BUCZKOWSKA M, Chattaway MA, Jenkins C, Hungerford D, et al
    Linking epidemiological and genomic data in cases of enteric fever in England to inform clinical management and public health action.
    J Antimicrob Chemother. 2024;79:1811-1819.
    >> Share

  366. LEE R, Nho D, Cho SY, Park S, et al
    Impact of an antimicrobial stewardship programme on antibiotic utilization and resistance burden in patients with acute leukaemia: an 11-year longitudinal cohort study using interrupted time-series analysis.
    J Antimicrob Chemother. 2024;79:1998-2007.
    >> Share

  367. YASUDA I, Toizumi M, Sando E
    Deleterious effects of a combination therapy using fluoroquinolones and tetracyclines for the treatment of Japanese spotted fever: a retrospective cohort study based on a Japanese hospital database.
    J Antimicrob Chemother. 2024;79:1962-1968.
    >> Share

  368. ZHANG MY, Li S, Wang CY, Zhang ZX, et al
    A novel antimicrobial peptide S24 combats serious wound infections caused by Pseudomonas aeruginosa and Acinetobacter baumannii.
    J Antimicrob Chemother. 2024;79:1951-1961.
    >> Share

  369. DE LA ROSA-RIESTRA S, Lopez-Hernandez I, Perez-Rodriguez MT, Sousa A, et al
    A comprehensive, predictive mortality score for patients with bloodstream infections (PROBAC): a prospective, multicentre cohort study.
    J Antimicrob Chemother. 2024;79:1794-1800.
    >> Share

  370. LOBERTTI CA, Cabezudo I, Gizzi FO, Blancato V, et al
    An allosteric inhibitor of the PhoQ histidine kinase with therapeutic potential against Salmonella infection.
    J Antimicrob Chemother. 2024;79:1820-1830.
    >> Share

  371. ZHANG X, Zeng W, Kong J, Huang Z, et al
    The prevalence and mechanisms of heteroresistance to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae.
    J Antimicrob Chemother. 2024;79:1865-1876.
    >> Share

  372. HASE R, Sakurai A, Suzuki M, Itoh N, et al
    Clinical characteristics and genome epidemiology of Stenotrophomonas maltophilia in Japan.
    J Antimicrob Chemother. 2024;79:1843-1855.
    >> Share

  373. WEBB EJD, Howdon D, Bestwick R, King N, et al
    The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study.
    J Antimicrob Chemother. 2024;79:1831-1842.
    >> Share

  374. THEODORE DA, Henneman AD, Loo A, Shields RK, et al
    Initial micafungin treatment does not improve outcomes compared to fluconazole treatment in immunocompromised and critically ill patients with candidaemia.
    J Antimicrob Chemother. 2024;79:1877-1884.
    >> Share

  375. FENG Y, Ding P, Shen J, Xu Y, et al
    Detection of cfr in Citrobacter braakii and the characterization of two cfr-carrying plasmids from a chicken farm.
    J Antimicrob Chemother. 2024;79:2071-2074.
    >> Share

  376. DWIBEDY SK, Padhy I, Panda AK, Mohapatra SS, et al
    Prevalence of polymyxin-resistant bacterial strains in India: a systematic review and meta-analysis.
    J Antimicrob Chemother. 2024;79:1762-1774.
    >> Share

    July 2024
  377. THANASAK J, Wongsurawat T, Jenjaroenpun P, Phumthanakorn N, et al
    Characterization of staphylococcal cassette chromosome mec in Staphylococcus haemolyticus ST3 and ST42 isolates from bovine mastitis milk: identification of novel variant in class C1 mec complex.
    J Antimicrob Chemother. 2024 Jul 31:dkae242. doi: 10.1093.
    >> Share

  378. BEADELL B, Yamauchi J, Wong-Beringer A
    Comparative in vitro efficacy of antibiotics against the intracellular reservoir of Staphylococcus aureus.
    J Antimicrob Chemother. 2024 Jul 29:dkae241. doi: 10.1093.
    >> Share

  379. ZHOU X, Yang M, Chen F, Wang L, et al
    Prediction of antimicrobial resistance in Klebsiella pneumoniae using genomic and metagenomic next-generation sequencing data.
    J Antimicrob Chemother. 2024 Jul 19:dkae248. doi: 10.1093.
    >> Share

  380. JING R, Yi QL, Zhuo C, Kang W, et al
    Establishment of epidemiological cut-off values for eravacycline, against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii and Staphylococcus aureus.
    J Antimicrob Chemother. 2024 Jul 16:dkae220. doi: 10.1093.
    >> Share

  381. SHI Q, Ruan Z, Zhang P, Hu H, et al
    Epidemiology of carbapenem-resistant Klebsiella pneumoniae in China and the evolving trends of predominant clone ST11: a multicentre, genome-based study.
    J Antimicrob Chemother. 2024 Jul 13:dkae227. doi: 10.1093.
    >> Share

  382. ZHOU H, Buetti N, Perez-Galera S, Bravo-Ferrer J, et al
    Risk factors for bloodstream infections due to carbapenem-resistant Enterobacterales: a nested case-control-control study.
    J Antimicrob Chemother. 2024 Jul 11:dkae157. doi: 10.1093.
    >> Share

  383. BAE J, Park JH, Lee M, Jo HJ, et al
    Clinicomicrobiological risk factors for infective endocarditis in viridans group streptococci bacteraemia.
    J Antimicrob Chemother. 2024 Jul 8:dkae231. doi: 10.1093.
    >> Share

  384. SHEEHY J, Scott AP, Henden AS, Kennedy G, et al
    Low rates of complications and beta-lactam resistance in viridans group streptococci bloodstream infection among cancer patients receiving chemotherapy.
    J Antimicrob Chemother. 2024 Jul 8:dkae209. doi: 10.1093.
    >> Share

  385. SHAH S, Clarke LG, Ludwig J, Burgdorf S, et al
    Carbapenem combination therapy versus standard of care for persistent methicillin-susceptible Staphylococcus aureus bacteraemia.
    J Antimicrob Chemother. 2024 Jul 1:dkae198. doi: 10.1093.
    >> Share

  386. HERMANN L, Schoning V, Drager S, Rentsch K, et al
    Population pharmacokinetics of flucloxacillin as intermittent bolus infusion in patients with Staphylococcus aureus bloodstream infection.
    J Antimicrob Chemother. 2024 Jul 1:dkae207. doi: 10.1093.
    >> Share

  387. VALDEZATE S, Medina-Pascual MJ, Villalon P, Garrido N, et al
    Co-occurrence of the cephalosporinase cepA and carbapenemase cfiA genes in a Bacteroides fragilis division II strain, an unexpected finding.
    J Antimicrob Chemother. 2024;79:1683-1687.
    >> Share

  388. ZHANG LC, Li QY, Zhang YQ, Shan TC, et al
    Population pharmacokinetics of daptomycin in critically ill patients receiving extracorporeal membrane oxygenation.
    J Antimicrob Chemother. 2024;79:1697-1705.
    >> Share

  389. DAABOUL D, Osman M, Kassem II, Yassine I, et al
    Neonatal sepsis due to NDM-1 and VIM-2 co-producing Pseudomonas aeruginosa in Morocco.
    J Antimicrob Chemother. 2024;79:1614-1618.
    >> Share

  390. CHARFI R, Tazi A, Sereme Y, Plainvert C, et al
    High-level expression of chromosomally encoded SHV-1 beta-lactamase reduces the susceptibility to cefiderocol of clinical isolates of Klebsiella pneumoniae.
    J Antimicrob Chemother. 2024;79:1711-1714.
    >> Share

  391. CANCELA COSTA A, Kritikos A, Glampedakis E, Da Silva Pereira Clara J, et al
    Antifungal drug penetration in soft tissue abscesses: a comparative analysis.
    J Antimicrob Chemother. 2024;79:1668-1672.
    >> Share

  392. IVANOVA M, Ovsepian A, Leekitcharoenphon P, Seyfarth AM, et al
    Azithromycin resistance in Escherichia coli and Salmonella from food-producing animals and meat in Europe.
    J Antimicrob Chemother. 2024;79:1657-1667.
    >> Share

  393. BIGHI N, Freitas F, Morgado S, Cipriano R, et al
    Deciphering the accessory genome of a novel Klebsiella pneumoniae lineage in the Brazilian Amazon region and its potential contribution to the emergence of a high-risk clone.
    J Antimicrob Chemother. 2024;79:1709-1711.
    >> Share

  394. CHEN PJ, Tan MC, Huang WC, Hsu SY, et al
    The individual contributions of blaB, blaGOB and blaCME on MICs of beta-lactams in Elizabethkingia anophelis.
    J Antimicrob Chemother. 2024;79:1577-1580.
    >> Share

  395. SUBBARAO S, Boyd SE, Basarab M, Riley P, et al
    Comment on: In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014-2019).
    J Antimicrob Chemother. 2024;79:1715-1716.
    >> Share

  396. TAYSI MR, Ocal D, Cicek Senturk G, Caliskan E, et al
    Implementation of the EUCAST rapid antimicrobial susceptibility test (RAST) for carbapenemase/ESBL-producing Escherichia coli and Klebsiella pneumoniae isolates, and its effect on mortality.
    J Antimicrob Chemother. 2024;79:1540-1546.
    >> Share

  397. WEERDENBURG H, Walker H, Curtis N, Duffull S, et al
    Posaconazole in paediatric malignancy and haematopoietic stem cell transplant: dosing to achieve therapeutic concentration.
    J Antimicrob Chemother. 2024;79:1493-1507.
    >> Share

  398. CADENAS-JIMENEZ I, Saiz-Escobedo L, Carrera-Salinas A, Camprubi-Marquez X, et al
    Molecular characterization of macrolide resistance in Haemophilus influenzae and Haemophilus parainfluenzae strains (2018-21).
    J Antimicrob Chemother. 2024 Jul 1:dkae214. doi: 10.1093.
    >> Share

    June 2024
  399. CHEN PY, Huang YS, Chuang YC, Wang JT, et al
    Implication of genotypes for prognosis of Candida glabrata bloodstream infections.
    J Antimicrob Chemother. 2024 Jun 22:dkae200. doi: 10.1093.
    >> Share

  400. WANG P, Liu S, He X, Miao W, et al
    Therapeutic drug monitoring of polymyxin B cerebrospinal fluid concentrations in patients with carbapenem-resistant Gram-negative bacteria-induced central nervous system infection.
    J Antimicrob Chemother. 2024 Jun 13:dkae193. doi: 10.1093.
    >> Share

  401. CHANCHAITHONG P, Chueahiran S, Pinpimai K, Sroithongkham P, et al
    Chromosomal and plasmid localization of ileS2 in high-level mupirocin-resistant Staphylococcus pseudintermedius and Staphylococcus aureus isolated from canine and feline origins.
    J Antimicrob Chemother. 2024 Jun 12:dkae172. doi: 10.1093.
    >> Share

  402. WESTON G, Giri A, Komarow L, Ge L, et al
    Clinical outcomes in patients infected with ertapenem-only-resistant Enterobacterales versus multi-carbapenem-resistant Enterobacterales.
    J Antimicrob Chemother. 2024 Jun 12:dkae186. doi: 10.1093.
    >> Share

  403. ALTARAWNEH H, Alhomra T, Alharbi M, Fan Y, et al
    Synergistic bactericidal activity of a novel dual beta-lactam combination against methicillin-resistant Staphylococcus aureus.
    J Antimicrob Chemother. 2024 Jun 4:dkae165. doi: 10.1093.
    >> Share

  404. RAHMAT ULLAH S, Jamal M, Rahman A, Andleeb S, et al
    Comprehensive insights into Klebsiella pneumoniae: unravelling clinical impact, epidemiological trends and antibiotic-resistance challenges.
    J Antimicrob Chemother. 2024 Jun 4:dkae184. doi: 10.1093.
    >> Share

  405. ELKAYAL O, Mertens B, Wauters J, Debaveye Y, et al
    Dosing of IV posaconazole to treat critically ill patients with invasive pulmonary aspergillosis: a population pharmacokinetics modelling and simulation study.
    J Antimicrob Chemother. 2024 Jun 3:dkae160. doi: 10.1093.
    >> Share

  406. MOURAD A, Smith AG, Troy JD, Holland TL, et al
    Clinical outcomes in patients with piperacillin/tazobactam-non-susceptible but ceftriaxone-susceptible E. coli or K. pneumoniae bloodstream infection.
    J Antimicrob Chemother. 2024;79:1456-1461.
    >> Share

  407. GAUTHIER A, Tlili L, Battu S, Le Moan C, et al
    Sedimentation field-flow fractionation for rapid phenotypic antimicrobial susceptibility testing: a pilot study.
    J Antimicrob Chemother. 2024;79:1450-1455.
    >> Share

  408. MARURI-ARANSOLO A, Lopez-Causape C, Hernandez-Garcia M, Garcia-Castillo M, et al
    In vitro activity of cefiderocol in Pseudomonas aeruginosa isolates from people with cystic fibrosis recovered during three multicentre studies in Spain.
    J Antimicrob Chemother. 2024;79:1432-1440.
    >> Share

  409. DURICEK M, Halmova K, Krutova M, Sykorova B, et al
    Is shorter also better in the treatment of Clostridioides difficile infection?
    J Antimicrob Chemother. 2024;79:1413-1417.
    >> Share

  410. BIENVENU AL, Cour M, Pavese P, Guichon C, et al
    Correlation between antifungal clinical practices and a new clinical decision support system ANTIFON-CLIC(R) for the treatment of invasive candidiasis: a retrospective multicentre study.
    J Antimicrob Chemother. 2024;79:1407-1412.
    >> Share

  411. LIU M, Wang M, Huang M, Gao Q, et al
    Iron efflux by IetA enhances beta-lactam aztreonam resistance and is linked to oxidative stress through cellular respiration in Riemerella anatipestifer.
    J Antimicrob Chemother. 2024;79:1385-1396.
    >> Share

  412. LEWIS R, Niazi-Ali S, McIvor A, Kanj SS, et al
    Triazole antifungal drug interactions-practical considerations for excellent prescribing.
    J Antimicrob Chemother. 2024;79:1203-1217.
    >> Share

  413. NAVICKAITE I, Holmes H, Dondi L, Randall L, et al
    Occurrence and characterization of rmtB-harbouring Salmonella and Escherichia coli isolates from a pig farm in the UK.
    J Antimicrob Chemother. 2024;79:1329-1336.
    >> Share

  414. KOLTE B, Nubel U
    Genetic determinants of resistance to antimicrobial therapeutics are rare in publicly available Clostridioides difficile genome sequences.
    J Antimicrob Chemother. 2024;79:1320-1328.
    >> Share

  415. KARAKITSIOS E, Dokoumetzidis A
    Extrapolation of lung pharmacokinetics of antitubercular drugs from preclinical species to humans using PBPK modelling.
    J Antimicrob Chemother. 2024;79:1362-1371.
    >> Share

  416. WANGCHINDA W, Pogue JM, Thamlikitkul V, Leelawattanachai P, et al
    Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections.
    J Antimicrob Chemother. 2024;79:1372-1379.
    >> Share

  417. NISSIM Y, LaSala PR, Slain D
    A serial passage experiment to assess the development of resistance to ertapenem and meropenem among Enterobacterales.
    J Antimicrob Chemother. 2024;79:1463-1466.
    >> Share

    May 2024
  418. GALAL L, Mohamed HS, Dupont C, Conquet G, et al
    Circulation of hypervirulent carbapenem-resistant Klebsiella pneumoniae in humans and fish in Djibouti.
    J Antimicrob Chemother. 2024 May 22:dkae144. doi: 10.1093.
    >> Share

  419. LEE YL, Wang WY, Ko WC, Hsueh PR, et al
    Global epidemiology and antimicrobial resistance of Enterobacterales harbouring genes encoding OXA-48-like carbapenemases: insights from the results of the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme 2018-2021.
    J Antimicrob Chemother. 2024 May 17:dkae140. doi: 10.1093.
    >> Share

  420. MILLS RO, Dadzie I, Le-Viet T, Baker DJ, et al
    Genomic diversity and antimicrobial resistance in clinical Klebsiella pneumoniae isolates from tertiary hospitals in Southern Ghana.
    J Antimicrob Chemother. 2024 May 16:dkae123. doi: 10.1093.
    >> Share

  421. MENENDEZ ALVARADO LR, Margulis Landayan A, Williams KN, Frederick CM, et al
    Impact of removing ESBL status labelling from culture reports on the use of carbapenems for non-bacteraemic patients diagnosed with ESBL-positive urinary tract infections.
    J Antimicrob Chemother. 2024 May 8:dkae135. doi: 10.1093.
    >> Share

  422. FOUAD A, Nicolau SE, Tamma PD, Simner PJ, et al
    Assessing the impact of meropenem exposure on ceftolozane/tazobactam-resistance development in Pseudomonas aeruginosa using in vitro serial passage.
    J Antimicrob Chemother. 2024;79:1176-1181.
    >> Share

  423. ZHENG M, Li FH, Liu J, Li WJ, et al
    Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae.
    J Antimicrob Chemother. 2024;79:1069-1080.
    >> Share

  424. GALANI I, Souli M, Katsala D, Karaiskos I, et al
    In vitro activity of apramycin (EBL-1003) in combination with colistin, meropenem, minocycline or sulbactam against XDR/PDR Acinetobacter baumannii isolates from Greece.
    J Antimicrob Chemother. 2024;79:1101-1108.
    >> Share

  425. MALLART E, Guerin F, Amoura A, Le Scouarnec M, et al
    Impact of the phenotypic expression of temocillin resistance in Escherichia coli on temocillin efficacy in a murine peritonitis model.
    J Antimicrob Chemother. 2024;79:1051-1059.
    >> Share

  426. UNEMO M, Golparian D, Oxelbark J, Kong FYS, et al
    Pharmacodynamic evaluation of ceftriaxone single-dose therapy (0.125-1 g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoea.
    J Antimicrob Chemother. 2024;79:1006-1013.
    >> Share

  427. BERGER A, Badell E, Ahman J, Matuschek E, et al
    Corynebacterium diphtheriae and Corynebacterium ulcerans: development of EUCAST methods and generation of data on which to determine breakpoints.
    J Antimicrob Chemother. 2024;79:968-976.
    >> Share

  428. URBANOWICZ P, Izdebski R, Biedrzycka M, Gniadkowski M, et al
    VIM-type metallo-beta-lactamase (MBL)-encoding genomic islands in Pseudomonas spp. in Poland: predominance of clc-like integrative and conjugative elements (ICEs).
    J Antimicrob Chemother. 2024;79:1030-1037.
    >> Share

  429. MAESTRO DE LA CALLE G, Velez J, Mateo Flores J, Garcia Barrio N, et al
    Assessment of risk-adjusted mortality ratio (RAMR) in bloodstream infections using all-patient refined diagnosis-related groups (APR-DRGs).
    J Antimicrob Chemother. 2024;79:1019-1022.
    >> Share

  430. SPERNOVASILIS N, Tsioutis C
    Not surprising: a rebound in antibacterial consumption in Europe, with Cyprus and Greece on the podium.
    J Antimicrob Chemother. 2024;79:933-934.
    >> Share

  431. DUQUE M, Bonnin RA, Dortet L
    Comparison of the French novel disc diffusion-based algorithm and the current EUCAST guidelines for the screening of carbapenemase-producing Enterobacterales.
    J Antimicrob Chemother. 2024;79:1194-1196.
    >> Share

    April 2024
  432. PHAISAL W, Albitar O, Chariyavilaskul P, Jantarabenjakul W, et al
    Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection.
    J Antimicrob Chemother. 2024 Apr 25:dkae059. doi: 10.1093.
    >> Share

  433. STEMKENS R, Mouhdad C, Franssen EJF, Touw D, et al
    Ten-year results of an international external quality control programme for measurement of anti-tuberculosis drug concentrations.
    J Antimicrob Chemother. 2024 Apr 6:dkae105. doi: 10.1093.
    >> Share

  434. WANGCHINDA W, Kaye KS, Patel TS, Albin OR, et al
    A comparison of strategies for identifying patients at risk for carbapenem-resistant or extended beta-lactam-resistant Pseudomonas aeruginosa.
    J Antimicrob Chemother. 2024 Apr 6:dkae104. doi: 10.1093.
    >> Share

  435. MACFADYEN AC, Paterson GK
    Methicillin resistance in Staphylococcus pseudintermedius encoded within novel staphylococcal cassette chromosome mec (SCCmec) variants.
    J Antimicrob Chemother. 2024 Apr 2:dkae096. doi: 10.1093.
    >> Share

  436. VAN INGEN J
    Why do we use 100 mg of clofazimine in TB and NTM treatment?
    J Antimicrob Chemother. 2024;79:697-702.
    >> Share

  437. RODRIGUEZ-OCHOA JL, Perez-Palacios P, Merino-Bohorquez V, Ortiz-Padilla M, et al
    Evaluation of temocillin efficacy against KPC-2-producing Klebsiella pneumoniae isolates in a hollow-fibre infection model.
    J Antimicrob Chemother. 2024;79:784-789.
    >> Share

  438. REYES BARROS T, Gutierrez Torres W, Garcia Canete P, Cerda Lorca J, et al
    Effect of different strategies for excluding duplicate cultures on the correlation between hospital resistance rates and antibiotic consumption.
    J Antimicrob Chemother. 2024;79:774-778.
    >> Share

  439. BOULEKBACHE A, Maldonado F, Kavafian R, Ferry T, et al
    Comparison of daptomycin and glycopeptide efficacy and safety for the treatment of Gram-positive infections: a systematic review and meta-analysis.
    J Antimicrob Chemother. 2024;79:712-721.
    >> Share

  440. DAABOUL D, Kassem II, Yassine I, Hamze M, et al
    Emergence of NDM-1, VIM-4 and CTX-M-15-co-harbouring Enterobacter xiangfangensis in a bloodstream infection.
    J Antimicrob Chemother. 2024;79:923-925.
    >> Share

  441. LAI T, Yeo CY, Rockliff B, Stokes M, et al
    Therapeutic drug monitoring of liposomal amphotericin B in children. Are we there yet? A systematic review.
    J Antimicrob Chemother. 2024;79:703-711.
    >> Share

    March 2024
  442. HARMER CJ, Cahill SM, Kenyon JJ, Hall RM, et al
    Aminoglycoside resistance genes in early members of the Acinetobacter baumannii ST78A (SMAL, Italian clone) reside in an IS26-bounded island in the chromosome.
    J Antimicrob Chemother. 2024 Mar 26:dkae064. doi: 10.1093.
    >> Share

  443. GOLPARIAN D, Bazzo ML, Ahlstrand J, Schorner MA, et al
    Recent dynamics in Neisseria gonorrhoeae genomic epidemiology in Brazil: antimicrobial resistance and genomic lineages in 2017-20 compared to 2015-16.
    J Antimicrob Chemother. 2024 Mar 22:dkae075. doi: 10.1093.
    >> Share

  444. PITT-KENDALL R, Sun S, Hughes S, Merrick R, et al
    Investigating the cause of increased tetracycline-resistant Neisseria gonorrhoeae in England, 2016-20.
    J Antimicrob Chemother. 2024 Mar 22:dkae073. doi: 10.1093.
    >> Share

  445. TESSIER E, Ruffier d'Epenoux L, Lartigue MF, Chaufour L, et al
    Comparison of the in vitro activities of delafloxacin and comparators against Staphylococcus epidermidis clinical strains involved in osteoarticular infections: a CRIOGO multicentre retrospective study.
    J Antimicrob Chemother. 2024 Mar 20:dkae071. doi: 10.1093.
    >> Share

  446. PHILIP A, Oueslati S, Villa F, Pannetier C, et al
    Development of an ultrafast PCR to detect clinically relevant acquired vancomycin-resistance genes from cultured enterococci.
    J Antimicrob Chemother. 2024 Mar 19:dkae062. doi: 10.1093.
    >> Share

  447. KITTL S, Brodard I, Tresch M, Perreten V, et al
    Novel tetracycline resistance gene tet(65) located on a multi-resistance Corynebacterium plasmid.
    J Antimicrob Chemother. 2024 Mar 18:dkae066. doi: 10.1093.
    >> Share

  448. YUNIVITA V, Gafar F, Santoso P, Chaidir L, et al
    Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia.
    J Antimicrob Chemother. 2024 Mar 9:dkae057. doi: 10.1093.
    >> Share

  449. ANJUM MF, Duggett N, Sheldon E, Sharma M, et al
    Genomics to detect transmission of livestock-associated methicillin-resistant Staphylococcus aureus from UK pigs in abattoirs during slaughter.
    J Antimicrob Chemother. 2024 Mar 5:dkae052. doi: 10.1093.
    >> Share

  450. CHEN RZ, Lu PL, Yang TY, Lin SY, et al
    Efficacy of cefoperazone/sulbactam for ESBL-producing Escherichia coli and Klebsiella pneumoniae bacteraemia and the factors associated with poor outcomes.
    J Antimicrob Chemother. 2024;79:648-655.
    >> Share

  451. MOREELS N, Boven A, Gressani O, Andersson FL, et al
    The combined effect of systemic antibiotics and proton pump inhibitors on Clostridioides difficile infection and recurrence.
    J Antimicrob Chemother. 2024;79:608-616.
    >> Share

  452. SELBY PR, Heffernan AJ, Yeung D, Warner MS, et al
    Population pharmacokinetics of posaconazole in allogeneic haematopoietic stem cell transplant patients.
    J Antimicrob Chemother. 2024;79:567-577.
    >> Share

    February 2024
  453. VAN HAL SJ, Jensen SO, Tong SYC, Bentley S, et al
    Unravelling the complex interplay between antibiotic consumption and adaptive changes in methicillin-resistant Staphylococcus aureus.
    J Antimicrob Chemother. 2024 Feb 27:dkae048. doi: 10.1093.
    >> Share

  454. FANG ZY, Zhang ZY, Zheng YD, Lei D, et al
    Repurposing cinacalcet suppresses multidrug-resistant Staphylococcus aureus by disruption of cell membrane and inhibits biofilm by targeting IcaR.
    J Antimicrob Chemother. 2024 Feb 27:dkae051. doi: 10.1093.
    >> Share

  455. BAYART J, Drouet J, Peycelon M, Mariani P, et al
    Temocillin for febrile urinary tract infections caused by ESBL-producing Enterobacteriaceae in children: a monocentric exposed/non-exposed study.
    J Antimicrob Chemother. 2024 Feb 27:dkae053. doi: 10.1093.
    >> Share

  456. COTRONEO N, Stokes SS, Pucci MJ, Rubio A, et al
    Efficacy of SPR720 in murine models of non-tuberculous mycobacterial pulmonary infection.
    J Antimicrob Chemother. 2024 Feb 23:dkae046. doi: 10.1093.
    >> Share

  457. JACQUELINE C, Samper-Cativiela C, Monzon Fernandez S, Ugarte-Ruiz M, et al
    Phenotypic and genetic characterization of antimicrobial resistance in Salmonella enterica serovar Choleraesuis isolates from humans and animals in Spain from 2006 to 2021.
    J Antimicrob Chemother. 2024 Feb 16:dkae029. doi: 10.1093.
    >> Share

  458. SOMAJO S, Nilsson F, Ekelund O, Unemo M, et al
    Detection of antimicrobial resistance in <5 h in Neisseria gonorrhoeae isolates using flow cytometry-proof of concept for seven clinically relevant antimicrobials.
    J Antimicrob Chemother. 2024 Feb 9:dkae034. doi: 10.1093.
    >> Share

  459. ROY S, Morita D, Bhattacharya S, Dutta S, et al
    Novel sequence type of carbapenem-resistant Acinetobacter pittii ST1451 with enhanced virulence isolated from septicaemic neonates in India.
    J Antimicrob Chemother. 2024 Feb 9:dkae024. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016